



(51) International Patent Classification:

A61B 5/024 (2006.01) A61B 5/08 (2006.01)
A61B 5/0456 (2006.01) A61B 5/00 (2006.01)
A61B 5/0488 (2006.01)

(21) International Application Number:

PCT/US2017/061099

(22) International Filing Date:

10 November 2017 (10.11.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/420,308 10 November 2016 (10.11.2016) US

(71) Applicant: **THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK** [US/US];
450 Clarkson Avenue, Box 0128, Brooklyn, New York 11203 (US).

(72) Inventors: **STEWART, Mark**; 98 River Road, East Hanover, New Jersey 07936 (US). **KOLLMAR, Richard**; Apt. 2A, 3611 Henry Hudson Parkway, Bronx, New York 10463 (US). **LAZAR, Jason**; 28 West Horseshoe Drive, Roslyn Heights, New York 10577 (US).

(74) Agent: **HOFFBERG, Steven**; Tully Rinckey PLLC, 777 Third Avenue, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SYSTEM, METHOD AND BIOMARKERS FOR AIRWAY OBSTRUCTION




Fig. 10

(57) Abstract: Two biomarkers are provided for obstructive apnea. A first biomarker determines amplitude and timing of inspiratory efforts from a bio-electric signal. The respiratory rate is compared with a normal pre-detection rate, and the amplitude of the effort is compared with a normal amplitude. The obstructive apnea is likely present if a series of inspiratory efforts are above a normal amplitude and with increasing amplitude, but at a normal rate. A second biomarker determines heart rate and respiratory rate. A normal lower threshold for heartbeat interval is established, and if subthreshold events occur (short RR intervals), a commencement time for each sequence of subthreshold events is compared for a respiratory rate-normalized window. If the number of subthreshold events exceeds a minimum for the window, obstructive apnea is likely present.

SYSTEM, METHOD AND BIOMARKERS FOR AIRWAY OBSTRUCTION

FIELD OF THE INVENTION

The present invention relates to the field of systems and methods for detecting obstructive
5 apnea or dyspnea, and biomarkers for obstructive apnea or dyspnea.

BACKGROUND OF THE INVENTION

Airway obstruction can be a critical health emergency, leading to death within minutes.
Partial obstruction is also possible.

Apnea is suspension of breathing. During apnea, the volume of the lungs initially remains
10 unchanged. Depending on how blocked the airways are (patency), there may or may not be a
flow of gas between the lungs and the environment; gas exchange within the lungs and cellular
respiration is not acutely affected.

In obstructive apnea, breathing is attempted, which causes increased activation of the
diaphragm and other muscles of respiration, including the intercostal muscles. After a few
15 minutes of prolonged apnea, blood oxygen falls, and various secondary responses occur.

Epileptic seizure is associated with obstructive apnea. Seizure activity spreads to laryngeal
motor neurons to cause laryngospasm. Laryngospasm results in partial or complete airway
occlusion. Seizure activity changes breathing frequency, amplitude, variability, and can cause
central apnea. Only obstructive apnea was associated with rapid, severe arterial oxygen
20 desaturation, bradycardia, and death. Sudden death is the result of respiratory arrest during
airway obstruction and nearly simultaneous LV dilatation and asystole. Sudden death in epilepsy
can be the result of seizure induced laryngospasm sufficient to cause obstructive apnea, which
leads to respiratory arrest and cardiac asystole within tens of seconds.

The recurrent laryngeal nerve (RLN) is a branch of the vagus nerve (cranial nerve X) that
25 supplies all the intrinsic muscles of the larynx, with the exception of the cricothyroid muscles.
These muscles act to open and close the vocal cords, and include the posterior cricoarytenoid
muscles, the only muscle to open the vocal cords. The nerves supply muscles on the same side of
the body, with the exception of the interarytenoid muscle, which is innervated from both sides.
See, en.wikipedia.org/wiki/Recurrent_laryngeal_nerve. The recurrent laryngeal nerves supply
30 sensation to the larynx below the vocal cords, gives cardiac branches to the deep cardiac plexus,
and branches to the trachea, esophagus and the inferior constrictor muscles. The posterior
cricothyroid muscles, the only muscles that can open the vocal cords, are innervated by this
nerve. The nerves also carry sensory information from the mucous membranes of the larynx

- 2 -

below the lower surface of the vocal fold, as well as sensory, secretory and motor fibers to the cervical segments of the esophagus and the trachea.

The MORTality in Epilepsy Monitoring Unit Study (MORTEMUS) identified a consistent sequence of events in epilepsy patients beginning with a generalized tonic clonic seizure and
5 ending in death [Ryvlin et al., Lancet Neurol. 12:966, 2013]. Ten cases were used to establish that the end of the seizure was followed within minutes by terminal apnea and ultimately cardiac arrest. Most importantly, this study established a singular pattern for their SUDEP cases.

U.S. 5,800,470, expressly incorporated herein by reference, discloses a respiratory muscle electromyographic rate responsive implantable pacemaker. The directly detected
10 electromyogram (EMG) signal is amplified and band passed filtered, processed to remove any electrocardiogram (ECG) or pacing impulse signal, full-wave rectified, processed to develop a moving time average signal from which the peak, the maximal slope, and the average slope of the EMG moving time average may be calculated and processed in conjunction with the
15 inspiratory and expiratory times between successive slope detections of the moving time average EMG to develop a rate control signal representative of ventilation rate. The EMG may be selectively picked up from electrodes implanted in or near the parasternal intercostal muscles, the external intercostal muscles, the internal intercostal muscles, the diaphragm, or any other respiratory muscle such as the scalenes, or the sternocleidomastoid, and coupled to
20 conventionally designed or special configuration pacemaker pulse generators and cardiac pace/sense lead systems.

U.S. 4,961,423, expressly incorporated herein by reference, proposes to employ specific electromyogram or EMG (a graph of electrical signals associated with muscle activity) signal processing circuitry in conjunction with a conventional cardiac pacing lead system to derive a control signal which reflects the patient's respiration as reflected across the electrodes in contact
25 with the patient's heart. By use of specific filtration and signal processing, it is proposed to separate the EMG signal from the electrocardiogram (ECG) signal and pacing stimulation impulse from the aggregate signal picked up across the pacing tip and can electrode pair or across separate electrodes devoted to the detection of the EMG.

Getzel et al., "Variation of Cardiac Pacemaker Rate Relative to Respiration," IEEE
30 Proceedings of 32nd CEMB, 1979, p. 123, and "Variation of Cardiac Pacemaker Rate Relative to Respiration," IEEE Trans. on Biomed. Eng., Vol. BME-26, No. 9, September 1979, p. 526., expressly incorporated orated herein by reference, describe the electronic integration of the

- 3 -

diaphragm electromyogram to generate a control signal proportional to respiratory minute volume for use as the controlling physiological input for a pacemaker.

US 2016/0089540, expressly incorporated herein by reference, a method of treating a patient, comprising: sensing a biological parameter indicative of respiration; analyzing the biological
5 parameter to identify a respiratory cycle; identifying an inspiratory phase of the respiratory cycle; and delivering stimulation to a hypoglossal nerve of the patient, wherein stimulation is delivered if a duration of the inspiratory phase of the respiratory cycle is greater than a predetermined portion of a duration of the entire respiratory cycle.

It is thus known that there is a respiration artifact in the ECG signal. It is also known that the
10 intrinsic ECG signal is respiratory responsive, including R-R interval.

Nakase et al., "Laryngospasm, central and obstructive apnea during seizures: Defining pathophysiology for sudden death in a rat model, *Epilepsy Research*, Volume 128 , 126 – 139 (Dec. 2016), DOI:dx.doi.org/10.1016/j.epilepsyres.2016.08.004; www.epires-
journal.com/article/S0920-1211(16)30124-3/abstract, describes the pathophysiology of sudden
15 death in epilepsy using an animal model, and has several figures that illustrate laryngospasm, obstructive apnea, desaturation during obstructive apnea, direct measures of the forces developed during attempts to inspire against a closed airway, and evidence of artifacts in ECG records.

Seizure spread into the autonomic nervous system is thought to play an important role in sudden unexpected death in epilepsy (SUDEP; (Bermeo-Ovalle et al., 2015; Devinsky, 2011; Lathers et al., 2008; Sakamoto et al., 2008; Shorvon and Tomson, 2011; Stewart, 2011; Surges
20 and Sander, 2012; Tolstykh and Cavazos, 2013)). Approximately 1% of the US population lives with epilepsy; depending on how one defines sudden death, 2%-17% of deaths in these patients are labeled SUDEP (e.g. (Nei and Hays, 2010)). Among adults with epilepsy, mortality rates are 2-3 times greater than among their non-epileptic counterparts (Langan, 2000; Thurman et al.,
25 2014), and SUDEP is the single most common cause of death (Lathers et al., 1998; Wannamaker, 1985).

Seizures are known to produce significant respiratory changes (reviewed in (Massey et al., 2014; Sowers et al., 2013)). Ictal apnea (Blum, 2009) is implicated in oxygen desaturation during seizures (Bateman et al., 2008; Seyal et al., 2010). Indeed, animal research established the
30 importance of ictal hypoxemia in seizure-induced death, as studies in sheep have shown that ictal hypoventilation leads to severe bradycardia and death (Johnston et al., 1995; Johnston et al., 1997). Similar findings have been noted in rats (Sakamoto et al., 2008; Stewart, 2011), cats (Schraeder and Lathers, 1983), and mice (Faingold et al., 2010; Uteshev et al., 2010). The

- 4 -

physiological mechanisms, however, that link seizures to respiratory dysfunction have not been fully resolved.

One possible cause of ictal respiratory distress is laryngospasm, a tonic adduction of the vocal folds that partially or fully obstructs the upper airway. Laryngospasm has been observed during seizures or postictally, evidenced by stridor and a narrowed airway when attempting to place an endotracheal tube (Tavee and Morris, 2008) or intensive inspiratory effort with severe air hunger (Amir et al., 1983). Cats and piglets experienced hypoventilation and glottal obstruction during chemically-induced seizures (Leaming et al., 1999; Terndrup et al., 1995a; Terndrup et al., 1995b). That pulmonary edema is the most common single finding at autopsy in SUDEP cases is also indirect evidence of laryngospasm (Antoniuk et al., 2001; Morentin and Alcaraz, 2002; Salmo and Connolly, 2002). Pulmonary edema can occur when “pulling” against a closed airway – the inspiratory effort increases pulmonary capillary pressure (Ead, 2003; Murray-Calderon and Connolly, 1997; Umbrain and Camu, 1993). Seizures could cause ictal laryngospasms by spreading via autonomic medullary motor regions to the laryngeal branches of the vagus nerve, the efferent innervation of the vocal folds.

A urethane/kainate rat model (reviewed in (Naggar and Stewart, 2015; Stewart, 2011)) was used to permit detailed study of laryngospasm during seizure activity. This model allows invasive monitoring during seizure activity. Recordings are obtained from the recurrent laryngeal nerve, the principal motor output to the larynx (Bartlett, 2011; Brancatisano et al., 1991; Kuna et al., 1991; Kuna et al., 1988; Kuna et al., 1990), along with simultaneous laryngoscopy (Mor et al., 2014) to define the patterns of RLN activity during seizures, the impact of seizure activity on laryngeal function, and the impact of laryngeal dysfunction on breathing. These data highlight the complexity of laryngospasm during seizures, and how changes in laryngeal function can contribute to death.

In order to monitor heart signals in an ambulatory environment, a number of options are available. Bioelectric signals may be acquired from the chest wall, limbs, and digits. Heart rate and pulse variability can also be acquired using pulse information, which can be acquired by plethysmography and optical sensors on the skin, wrist, ankle, and digits.

See:

www.vitalconnect.com/upload/Documents/EngeryExpenditure2014_MobiHealth_published.pdf;
www.vitalconnect.com/upload/Documents/Longterm-Remote-Monitoring_HealthInnovations_2014_published.pdf;
www.vitalconnect.com/upload/Documents/AutomatedPrediction_2014_IEEE_published.pdf;

www.vitalconnect.com/upload/Documents/2014-Sleep-Abstract.pdf;

www.vitalconnect.com/upload/press/Chan2013EMBC_VitalConnectPatch.pdf;

www.vitalconnect.com/upload/press/Selvaraj2013EMBC_OSAeventDetectionRespiratorySignals.pdf;

www.vitalconnect.com/upload/press/Chan2013EMBC_RespirationECGandAccelerometer.pdf;

- 5 Rosenberg M., Samuel M., Thosani A., Zimetbaum P., “Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study”, *Pacing Clin Electrophysiol.* 2013;36(3): 328-333.

See also, U.S. Patent and Pub. Patent App. Nos. 3942513; 3950799; 4033332; 4169462;

- 4197856; 4289142; 4350166; 4381788; 4387722; 4391279; 4403215; 4422458; 4446869;
10 4474185; 4475559; 4506626; 4558708; 4595016; 4630614; 4657026; 4686975; 4694839;
4715367; 4724844; 4732159; 4736749; 4745925; 4757824; 4757825; 4765340; 4802485;
4802486; 4803997; 4806112; 4838279; 4889116; 4895162; 4924860; 4928692; 4928703;
4958638; 4961423; 4982738; 5005234; 5005571; 5016636; 5036852; 5052400; 5095900;
5099836; 5107855; 5131387; 5133346; 5206807; 5271412; 5295490; 5307817; 5309921;
15 5311875; 5353793; 5360008; 5395301; 5485850; 5495242; 5603316; 5645053; 5671733;
5704345; 5765554; 5769084; 5779631; 5782240; 5792068; 5800360; 5800470; 5825293;
5853005; 5873821; 5879313; 5913826; 5928157; 5954053; 5961447; 5964720; 6017315;
6019732; 6029665; 6045514; 6062216; 6064910; 6134460; 6138675; 6150104; 6150941;
6168568; 6208897; 6223064; 6241683; 6248068; 6261238; 6267730; 6286508; 6290654;
20 6342039; 6342040; 6363933; 6368287; 6375621; 6390987; 6450168; 6454724; 6470888;
6477710; 6498652; 6510339; 6537228; 6544192; 6549795; 6550478; 6553242; 6553256;
6574507; 6580943; 6580944; 6621278; 6675797; 6721980; 6773404; 6785568; 6816266;
6849049; 6856141; 6881192; 6915705; 6920877; 6970737; 6984993; 6989744; 7020511;
7035432; 7039152; 7074177; 7080554; 7092755; 7117036; 7126467; 7129833; 7148797;
25 7166123; 7168429; 7170404; 7173525; 7179229; 7225021; 7269459; 7315760; 7320320;
7330127; 7340302; 7363086; 7391316; 7403110; 7415093; 7431700; 7435221; 7460899;
7467012; 7473227; 7477142; 7477143; 7477144; 7508307; 7515059; 7522035; 7533571;
7593764; 7597659; 7611472; 7656287; 7661426; 7667624; 7678058; 7711579; 7715905;
7716767; 7725181; 7730886; 7734335; 7794716; 7800505; 7811234; 7818058; 7827988;
30 7884735; 7894849; 7899521; 7909764; 7938114; 7942822; 7976470; 7988640; 8011365;
8031080; 8050765; 8106781; 8119134; 8121692; 8136521; 8142343; 8155735; 8161971;
8204580; 8219185; 8226570; 8226571; 8238996; 8255029; 8258973; 8262578; 8273053;
8301219; 8301232; 8360060; 8360983; 8381722; 8393233; 8396537; 8403861; 8417351;

- 6 -

8442578; 8449473; 8482418; 8483807; 8483811; 8483834; 8489182; 8509882; 8527028;
8538510; 8551010; 8554323; 8560044; 8562526; 8566115; 8568160; 8579792; 8595164;
8616203; 8630704; 8641631; 8683999; 8700137; 8718751; 8721554; 8721560; 8721573;
8731644; 8750987; 8752547; 8768731; 8790270; 8801620; 8828386; 8844525; 8862211;
5 8868152; 8880207; 8892194; 8923971; 8948854; 8954137; 8983587; 8985106; 9019100;
9022032; 9024781; 9026202; 9037477; 9044362; 9078577; 9089691; 9101277; 9113788;
9131892; 9132250; 9144389; 9177459; 9180270; 9192336; 9198616; 9198617; 9199053;
9202084; 9215075; 9216291; 9220459; 9220460; 9227034; 9269000; 9277867; 9302116;
9307921; 9333318; 9364180; 9370634; 9414787; 9415182; 9445736; 9445740; 9445747;
10 9451888; 9468835; 9477812; D284697; RE32180; 20010018557; 20010044588; 20020007126;
20020078957; 20020099300; 20020105340; 20020161290; 20020173707; 20030024528;
20030111079; 20030161436; 20030161440; 20030163059; 20030199945; 20030208130;
20030213488; 20030236548; 20040002742; 20040082874; 20040104733; 20040123866;
20040158193; 20040186523; 20040187870; 20040194220; 20040207409; 20040257233;
15 20050027204; 20050027206; 20050053262; 20050085736; 20050085863; 20050085865;
20050101833; 20050113656; 20050177051; 20050211248; 20050211249; 20050273361;
20050277842; 20050288572; 20060000475; 20060004245; 20060011200; 20060025696;
20060025697; 20060030894; 20060050930; 20060087325; 20060122675; 20060134106;
20060179571; 20060229489; 20060258916; 20060258921; 20060264770; 20070061393;
20 20070062540; 20070073177; 20070100381; 20070106536; 20070106537; 20070106750;
20070106751; 20070106752; 20070106753; 20070106754; 20070116036; 20070116037;
20070142713; 20070142741; 20070167694; 20070168461; 20070199262; 20070215146;
20070255310; 20070265539; 20070282212; 20080009755; 20080015454; 20080015457;
20080039730; 20080040151; 20080041382; 20080041383; 20080045832; 20080051845;
25 20080058873; 20080058892; 20080060138; 20080071185; 20080082016; 20080091082;
20080092898; 20080101532; 20080154110; 20080161708; 20080163873; 20080167567;
20080170654; 20080177789; 20080183095; 20080183239; 20080190430; 20080190436;
20080243021; 20080262360; 20080287769; 20080287770; 20080288013; 20080300499;
20080308112; 20080313816; 20080319513; 20090036790; 20090099462; 20090099469;
30 20090118629; 20090149778; 20090172773; 20090177050; 20090177495; 20090183312;
20090203972; 20090226861; 20090226862; 20090226863; 20090226864; 20090226865;
20090270773; 20090318820; 20090326981; 20100004549; 20100010359; 20100016783;
20100018530; 20100036209; 20100036263; 20100036268; 20100036269; 20100056850;

- 7 -

20100063438; 20100099963; 20100137723; 20100159426; 20100168578; 20100179396;
20100198083; 20100198289; 20100204550; 20100222685; 20100222689; 20100228120;
20100242965; 20100252037; 20100252039; 20100252040; 20100252041; 20100252042;
20100253505; 20100258123; 20100262035; 20100268093; 20100297129; 20100307500;
5 20100328075; 20110009722; 20110011402; 20110021970; 20110034820; 20110105921;
20110131057; 20110160601; 20110172552; 20110184298; 20110184304; 20110190651;
20110214676; 20110245706; 20110284003; 20110301435; 20110301439; 20110319777;
20120004749; 20120028504; 20120029362; 20120032778; 20120046709; 20120056746;
20120088998; 20120101690; 20120109027; 20120130204; 20120130446; 20120136231;
10 20120152252; 20120160243; 20120165711; 20120172689; 20120173470; 20120189632;
20120197144; 20120203491; 20120209096; 20120232398; 20120232416; 20120240934;
20120252709; 20120272429; 20120283527; 20120323104; 20120330123; 20130012827;
20130030711; 20130046151; 20130046156; 20130046157; 20130046160; 20130046161;
20130046184; 20130046185; 20130046186; 20130046187; 20130046188; 20130053674;
15 20130060480; 20130081479; 20130085688; 20130096447; 20130096450; 20130123654;
20130131522; 20130165809; 20130174847; 20130178719; 20130211210; 20130218030;
20130234535; 20130255683; 20130261485; 20130268030; 20130281815; 20130291060;
20130296660; 20130300575; 20130307685; 20130312752; 20130312757; 20130331663;
20130340500; 20140012145; 20140018779; 20140025141; 20140031705; 20140031709;
20 20140058274; 20140066741; 20140066798; 20140073969; 20140094669; 20140100628;
20140107501; 20140150793; 20140152467; 20140163343; 20140163386; 20140171783;
20140180148; 20140180154; 20140218210; 20140221859; 20140228651; 20140243934;
20140246024; 20140246025; 20140258743; 20140276287; 20140309568; 20140309943;
20140320309; 20140323946; 20140330155; 20140330540; 20140363740; 20140364706;
25 20150005646; 20150018660; 20150035643; 20150038867; 20150039110; 20150065891;
20150073285; 20150101609; 20150112202; 20150119739; 20150126847; 20150141766;
20150141862; 20150150500; 20150173672; 20150182132; 20150182842; 20150216448;
20150228176; 20150251016; 20150257653; 20150305634; 20150314098; 20150320588;
20150321022; 20150359964; 20150366511; 20150370320; 20150374328; 20160004820;
30 20160022145; 20160022204; 20160030689; 20160045134; 20160045166; 20160045167;
20160045654; 20160045695; 20160066805; 20160066809; 20160074606; 20160089540;
20160095997; 20160100798; 20160120430; 20160120431; 20160120433; 20160120434;
20160128209; 20160135706; 20160143594; 20160169930; 20160174857; 20160220197;

- 8 -

20160228024; 20160228060; 20160256063; 20160256644; 20160263393; 20160278658;
20160296124; 20160302726; and 20160310103.

A fingertip electrometer-based cardiac cycle sensors is disclosed in US 2012/0004523.

- 9 -

SUMMARY OF THE INVENTION

Seizures are known to produce significant respiratory changes and seizure spread into the autonomic nervous system can result in life-threatening cardiovascular and respiratory dysfunction. Ictal apnea and/or ictal bradycardia has been well recognized as a part of the

5 autonomic manifestation in epileptic seizures. Prolonged peri-ictal apnea and bradycardia are both regarded as risk factors for sudden death in epilepsy (SUDEP). SUDEP is the major cause of death among persons with epilepsy. However, the physiological mechanisms of SUDEP are poorly understood and no specific indicator of SUDEP events is known. One possible cause of ictal respiratory distress is laryngospasm, a tonic adduction of the vocal folds that partially or
10 fully obstructs the upper airway. Using a rat model, sudden death due to seizure and hypoxemia-induced conditions was studied. Based on findings of the inventors, some seizures cause laryngospasm that is sufficiently severe to produce complete airway obstruction. Once occluded, attempts to inspire against a closed airway get progressively stronger until attempts stop (the point of respiratory arrest). These attempts produce clear artifacts in recordings of
15 electrocardiogram (ECG) and electroencephalogram (EEG) signals whose amplitudes highly correlate with the force of attempted inspiration. Late in the occlusion, the RR interval variability is dramatically increased due to an overall slower heart rate in combination with additional very short RR intervals closely associated with attempts to inspire.

Artifacts in the ECG and EEG during obstructive apnea caused by laryngospasm correspond
20 in time and correlate in size with a direct measure of inspiratory effort in experimental animals. Likewise, these inspiration efforts cause strong electromyography (EMG) signals from muscles of respiration, including diaphragm and intercostal muscles while the resulting hypoxemia leads to bradycardia and an abrupt increase in heart rate variability with very short RR intervals at the time of each attempted inspiration.

25 R waves in ECG can be automatically identified through RR interval analyses and artifact detection and quantification from ECG and EEG records.

These physiological effects detected by these signals and analyzed can be used as practical biomarkers of obstructive apnea (e.g. laryngospasm). Two particular biomarkers that are specific for upper airway occlusion include:

- 30 - a high frequency EMG signal superimposed on the ECG signal
- a variation in R-R wave intervals

The high frequency signal has an amplitude that corresponds to inspiratory effort, and therefore by monitoring respiration artifacts over time, an adaptive baseline may be established.

- 10 -

When an obstructive apnea occurs, the respiratory artifacts are altered in a distinctive way. The amplitude increases on successive attempts, and the timing of these attempts differs from a normal respiratory rate. Both the high frequency signal and the variation in R-R wave intervals are responsive to obstructive apnea and indicative of an apnea activity pattern of muscles of respiration, including diaphragm and intercostal muscles.

Because these biomarkers do not require ECG analysis per se, they may be detected from electrodes in non-standard locations for cardiac monitoring, such as fingers or wrist. As such, the monitoring device may take the form of a wrist-band, ring(s), or other convenient form. Of course, traditional chest electrodes may also be employed.

The R-R interval is the basic heart rate, and therefore the rate and its variability can be determined in an alternate manner, e.g., without electrocardiographic electrodes. For example, physical or optical pulse sensors, acoustic sensors, ballistocardiographic sensors, etc.

On the other hand, the high frequency electromyographic signal from muscles of respiration, including diaphragm and intercostal muscles, superimposed on the electrocardiographic signal would generally require an electronic sensor for detection. However, other types of respiratory sensors and detection may be employed, though when directly measuring respiration, the need for a biomarker or indirect measurement for apnea is diminished.

The combination of these biomarkers clearly indicates when a person's breathing is obstructed, attempting to breathe, and generating large breathing forces in these attempts. An alarm sounded at this point to alert a caretaker will permit enough time to ensure that respiratory arrest does not occur or that, if respiratory arrest does occur, resuscitation steps can be taken to save a life. These biomarkers can also be applied to past cases and used to monitor patients to improve outcomes.

These biomarkers may have application in various types of obstructive apnea. While a preferred system and method target ictal obstructive apneas, asthmatic conditions may produce similar biomarkers. Thus, when an asthmatic attack occurs, airways are restricted, leading to reduced chest pressure and large inspiratory efforts. Asthmatic apnea tends to be an incomplete blockage, and therefore the pattern over time may differ from a laryngospasm-induced apnea, but the biomarkers are sufficiently broad to permit application in various uses.

In the case of asthma, one might seek to determine the extent of blockage, which is not always directly apparent, especially in exercise induced-asthma, where increased demand is superimposed on the airway restriction. However, the restriction will increase the efforts

- 11 -

required, and increase the pressure differentials, and thus the asthmatic restriction may be distinguished from the mere increased respiratory rate due to exertion.

Based on these biomarkers, a system and method is provided that can detect the period of obstructive apnea and be used to sound an alarm in time to prevent respiratory arrest or in time to permit resuscitation.

A particular aspect of the system and method is the extraction of one or both of the biomarkers from ECG data, EEG data, or other bioelectric signals. The data used for biomarker extraction can thus come from multiple sources. In circumstances where ECG data or EEG data is already collected and available for analysis, e.g. any continuous ECG recording or EEG recording in a hospital setting, such as that used in Critical Care Units, Epilepsy Monitoring Units, etc., the biomarker identification algorithms can be added to the existing instrumentation. In an ambulatory or home setting, ECG can be obtained by a minimally intrusive "bracelet" such as those used for popular HR monitoring, with the exception that a telemetry component would generally be added to the bracelet and the receiving station, e.g., smartphone, would house the biomarker detection software and the hardware used for the alarm. A hat or scalp monitor with electrodes can also provide EEG data.

Of course, the data analysis can be provided within the sensor module, and an audible and/or visual alarm sounded from the module. Sensing obstruction may incur a latency, of approximately 10-30 seconds, and the time before permanent damage occurs to the patient is only a few minutes, providing only a small window of opportunity to prevent a complete laryngeal obstruction of the patients airway, and therefore a local caregiver would need to provide immediate assistance, and remote monitoring would likely be ineffective. However, within a hospital or other facility, a remote, wireless alarm may be useful. Similarly, in cases of incomplete obstruction, such as bronchial constriction, the onset and resolution of the apnea provide a larger window of opportunity for intervention.

Biomarker extraction involves taking the ECG signal and processing it in different ways for each of the two biomarkers.

BIOMARKER I

The algorithm for biomarker I (Artifact Growth) involves the following steps applied to ECG recorded with a bandwidth of approximately 10 Hz to > 1 kHz:

1. Secondary filter applied to data to pass approximately 300 Hz to 1 kHz.
2. Detect and measure breathing artifacts by methods such as rectification and integration or signal "envelope" quantification.
3. Compare values to amplitude threshold.
4. Hold value and time of events above threshold.
5. Compare interval between successive events with window established for respiratory rate.
6. Sound alarm if:
 - a) 3 successive events are above threshold, and

- 12 -

- b) the interval between events is appropriate for respiratory rate, and
- c) the event amplitude is steady or increasing.

More generally, a bioelectric signal is obtained which includes a contribution from activity of muscles of respiration, including diaphragm and intercostal muscles activity. The bioelectric signal is processed to represent amplitude and timing of inspiratory efforts. The respiratory rate is compared with a normal pre-detection rate, and the amplitude of the bioelectric signal is compared with a pre-detection normal amplitude. The obstructive apnea is likely present if a series of inspiratory efforts are above a normal amplitude and with increasing amplitude, but at a normal rate.

BIOMARKER 2

The algorithm for biomarker 2 (Ultrashort RR Intervals) involves analysis of the acquired ECG signal with the following steps:

1. Detect R waves.
2. Measure RR intervals.
3. Compare interval to baseline range.
4. If ultrashort interval detected (RR interval is below threshold), store value and time of event.
5. Immediately successive short intervals are stored as a single event.
6. Compare time between successive events to the window established for respiratory rate.
7. Sound alarm if:
 - a) 3 sets of short intervals are spaced by the respiratory interval.

More generally, the heart rate is determined, and compared to a baseline average. A normal lower threshold is established, and if subthreshold events occur (short RR intervals), a commencement of each sequence of subthreshold events is compared for a respiratory rate-normalized window. If the number of subthreshold events exceeds a minimum for the window, obstructive apnea is likely present.

The technology may be implemented in any device that receives a bioelectric signal that includes electromyographic signals emanating from muscles of respiration. For example, an automated external defibrillator (AED) device may be provided with program instructions that permit the ECG electrodes to read the electromyographic signals, and provide obstructive apnea indication, in addition to the normal defibrillator functionality. As noted, the present system seeks to compare a current bioelectric signal with a baseline signal, which may not be available in an acute emergency. Likewise, the AED tends to be employed with a human user in attendance, who can observe the patient. However, the user may be untrained, and therefore automatically monitoring the patient for apnea, and to distinguish different types of apnea, may be useful, especially for differential diagnosis where a patient hooked to the AED has a normal sinus rhythm, and yet is in distress.

- 13 -

It is therefore an object to provide a method for detecting obstructive apnea, comprising: receiving a bioelectric signal from a mammal comprising electromyographic activity of muscles of respiration, including diaphragm and intercostal muscles; processing the bioelectric signal to isolate the electromyographic activity; determining a timing and amplitude of inspiratory efforts
5 based on the isolated electromyographic activity; determining a baseline amplitude of inspiratory efforts; comparing an amplitude of inspiratory efforts with the determined baseline amplitude of inspiratory efforts; and determining occurrence of obstructive apnea if a series of inspiratory efforts have increasing amplitude over time, above the baseline amplitude.

The method may further comprise determining a baseline timing of inspiratory efforts, and
10 comparing the timing of inspiratory efforts with the determined baseline timing of inspiratory efforts, wherein the occurrence of obstructive apnea is determined if a series of inspiratory efforts have increasing amplitude above the baseline amplitude over time, and a baseline timing.

The timing and amplitude of inspiratory efforts may be determined over a series of three inspiratory efforts before the occurrence of obstructive apnea is determined.

15 The bioelectric signal may be an electrocardiographic signal. The bioelectric signal may be an electroencephalographic signal. The bioelectric signal may be acquired from a single extremity.

The method may further comprise generating an audible alarm in response to determining the occurrence of obstructive apnea. The method may further comprise generating a wireless
20 communication in response to determining the occurrence of obstructive apnea.

The bioelectric signal may be received from a mammal comprising electromyographic activity of muscles of respiration, including diaphragm and intercostal muscles comprises receiving at least one of an electrocardiographic signal, an electroencephalographic signal, and an electromyographic signal. The processing of the bioelectric signal may be used to isolate
25 electromyographic activity comprises subjecting the bioelectric signal to a bandpass filter having a passband between about 300 Hz and 1 kHz. The processing of the bioelectric signal may be used to isolate electromyographic activity comprises determining a signal power within a passband over time.

The comparing of an amplitude of inspiratory efforts with the determined baseline amplitude
30 of inspiratory efforts may comprise comparing a series of amplitudes and timings of inspiratory efforts with a baseline window representing a normal range of amplitudes and timings of inspiratory efforts.

- 14 -

The occurrence of obstructive apnea may be determined if a series of inspiratory efforts have increasing amplitude over time, above the baseline amplitude, comprises determining if three successive inspiratory efforts have an amplitude above a threshold with at least one of a steady amplitude and an increasing amplitude, while an interval between inspiratory efforts is within a normal range.

It is also an object to provide a method of determining obstructive apnea, comprising: determining a baseline inter-heartbeat interval and a normal range of variation for a respective respiratory rate within a respiratory interval; determining an inter-heartbeat interval and a respiratory rate of a patient; determining a commencement of a series of inter-heartbeat intervals which is outside the normal range of variation below the baseline inter-heartbeat interval for the respective respiratory rate; and determining commencement of obstructive apnea if a number of commencements of the series of at least one inter-heartbeat interval which is below the baseline inter-heartbeat interval for the respective respiratory rate within the respiratory interval is above a threshold. The threshold may be three.

The inter-heartbeat interval and the respiratory rate may be determined based on a bioelectric signal.

The bioelectric signal may be an electrocardiographic signal, an electroencephalographic signal, and/or an electromyographic signal. The bioelectric signal may be acquired from a single extremity.

The method may further comprise generating an audible alarm in response to determining the commencement of obstructive apnea. The method may further comprise generating a wireless communication in response to determining the commencement of obstructive apnea. The method may further comprise automatically generating an e911 (enhanced 911) call through a telephone network in response to determining the commencement of obstructive apnea.

The inter-heartbeat interval may be determined by determining an R-R interval of an electrocardiogram.

The method may further comprise establishing a window distinguishing a normal inter-heartbeat interval from a short inter-heartbeat interval for the respective respiratory rate; and recording a time of an inter-heartbeat interval which is outside the window for the respective respiratory rate.

It is a further object to provide a system for detecting obstructive apnea, comprising: an input configured to receive a bioelectric signal from a mammal comprising electromyographic activity of muscles of respiration, including diaphragm and intercostal muscles; at least one processor

- 15 -

configured to: process the bioelectric signal to isolate electromyographic activity; determine a timing and amplitude of inspiratory efforts based on the isolated electromyographic activity; determine a baseline amplitude of inspiratory efforts; compare an amplitude of inspiratory efforts with the determined baseline amplitude of inspiratory efforts; and determine occurrence of
 5 obstructive apnea if a series of inspiratory efforts have increasing amplitude over time, above the baseline amplitude; and an output for communicating an alarm dependent on the determined occurrence.

It is another object to provide a system for of determining obstructive apnea, comprising: an input configured to receive information defining an inter-heartbeat interval; at least one
 10 processor configured to: determine a baseline inter-heartbeat interval and a normal range of variation for a respective respiratory rate within a respiratory interval; determine an inter-heartbeat interval and a respiratory rate of a patient; determine a commencement of a series of inter-heartbeat intervals which is outside the normal range of variation below the baseline inter-heartbeat interval for the respective respiratory rate; and determine commencement of
 15 obstructive apnea if a number of commencements of the series of at least one inter-heartbeat interval which is below the baseline inter-heartbeat interval for the respective respiratory rate within the respiratory interval is above a threshold; and an output for communicating an alarm dependent on the determined commencement.

These and other objects will become apparent through a review of the description hereof.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1A shows artifacts enhanced in EEG and ECG by highpass filtering. Arrows indicate last breath attempt.

Fig. 1B shows correlations of ECG and EEG artifacts with peak inspiratory pressure (PIP).

Fig. 1C shows a plot of RR over time (bottom), PIP during obstruction (middle) and PIP peak markers (top). RR variance increases late in the occlusion.

Fig. 1D shows the standard deviation of the RR intervals (n=16 animals).

Fig. 1E shows plots of RR intervals as function of the time relative to the PIP (n=16 animals).

Fig. 2 shows extreme increases in RLN activity during a seizure.

Fig. 3 shows plethysmography during kainic acid-induced seizure activity.

Fig. 4A shows a graph of movement of arytenoid cartilage over time, and Fig. 4B shows a graph of average glottis opening during seizures over time, demonstrating show irregular vocal fold movement during seizure activity.

Fig. 5 shows obstructive and central apnea during seizures.

- 16 -

Fig. 6 shows recurrent laryngeal nerve activity during obstructive and central apnea.

Fig. 7 shows a laryngoscope view, plethysmograph trace, ECG, and EEG (x2) tracings in a baseline state (left), hemiparetic (middle), and laryngospasm (right) states.

5 Fig. 8 shows concurrent tracings of ECG (top), pulse oximeter (second from top), airway pressure (second from bottom), and blood pressure (bottom) during upper airway occlusion.

Fig. 9 shows echocardiography during controlled airway occlusion.

10 Fig. 10 shows a graph of a pilot test in human subjects of biomarker 1 (the increased peak-to-peak amplitude of an ECG recording's background activity, which is due to increase thoracic muscular EMG getting included in the ECG signal) during attempts to inspire against an occluded upper airway.

Fig. 11 shows a summary of cardiac and respiratory parameters during controlled airway occlusion.

Figs. 12 and 13 show various prior art ECG acquisition systems.

Fig. 14 shows a prior art ECG analog acquisition and wireless transmitter system.

15 Figs. 15 and 16 show semi-schematic drawings of the prior art ECG wireless transmitter system and ECG analog acquisition system of Fig. 14.

Fig. 17 shows a prior art flow diagram for algorithm implementation of the prior art ECG analog acquisition and wireless transmitter system according to Fig. 14.

Fig. 18 shows a block diagram of a prior art electronic device according to US 2016/0128209.

20 Fig. 19 is a diagram illustrating a network environment including an electronic device according to US 2016/0128209.

- 17 -

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

EXAMPLE 1

Parenteral kainic acid was used to induce recurring seizures in urethane-anesthetized Sprague Dawley rats. EEG recordings and combinations of cardiopulmonary monitoring, including video laryngoscopy, were performed during multi-unit recordings of recurrent laryngeal nerve (RLN) activity or head-out plethysmography with or without endotracheal intubation. Controlled occlusions of a tracheal tube were used to study the kinetics of cardiac and respiratory changes after sudden obstruction. Seizure activity caused significant firing increases in the RLN that were associated with abnormal, high-frequency movements of the vocal folds. Partial airway obstruction from laryngospasm was evident in plethysmograms and was prevented by intubation. Complete glottic closure (confirmed by laryngoscopy) occurred in a subset of non-intubated animals in association with the largest increases in RLN activity, and cessation of airflow was followed in all obstructed animals within tens of seconds by ST-segment elevation, bradycardia, and death.

Periods of central apnea occurred in both intubated and non-intubated rats during seizures for periods up to 33 seconds and were associated with modestly increased RLN activity, minimal cardiac derangements, and an open airway on laryngoscopy.

For controlled airway occlusion, a T-tube was inserted into the distal trachea of urethane-anesthetized rats. EEG, ECG, and inspiratory pressure at the sidearm of the T-tube were bandpass-filtered from 1 Hz to 1 kHz. The open port of the T-tube was occluded for 100 seconds or until respiratory arrest. Inspiration artifacts in the EEG and ECG records were isolated with a digital high-pass filter (corner frequency 367 Hz, rolloff -3 dB/octave) and quantified by full-wave rectification. Inspiration artifacts matched the inspiratory pressure extrema during airway occlusion. Correlations (r) of peak inspiratory pressure to artifact amplitude in a within-animal comparison were -0.88 (ECG) and -0.75 (EEG), suggesting that artifacts extracted from ECG records may be better than those derived from EEG records. The average correlation of artifact magnitude (ECG) with peak inspiratory pressure was -0.89 ± 0.04 ($N=5$ rats). The results suggest that a sudden increase in the amplitude of the inspiratory artifact in EEG and ECG recordings indicates an occluded airway, and a very high correlation of increasing inspiration artifact size with increasing inspiratory effort was observed. This artifact pattern could serve as a biomarker in two important ways: First, to review existing records for the possible contribution of obstructive apnea to documented SUDEP cases. Second, to warn about obstructive apnea in patients being monitored in real time. The specificity of the biomarker would be further enhanced by marking decreases in seizure activity and heart rate. To maximize the sensitivity of the biomarker, EEG and ECG should be recorded at the highest bandwidth possible (within the capability of the available equipment, e.g., up to 10 kHz

- 18 -

bandwidth). The most attractive feature of this biomarker is that it can be derived from commonly-used measures in epilepsy-monitoring units and even potentially portable devices outside of the hospital.

Using a rat model that permits simultaneous autonomic, cardiovascular, and respiratory monitoring, it was demonstrated that seizure-induced laryngospasm caused obstructive apnea, which stopped the seizure and persisted until respiratory arrest, followed by cardiac arrest. The MORTEMUS study used artifacts in EEG recordings as evidence of respiration. A critical finding herein is that attempts to breathe during obstruction generated artifacts in EEG and ECG recordings that resembled artifacts associated with actual breaths.

The electrical artifacts of attempts to inspire during airway obstruction can be used as a practical biomarker of obstructive apnea. In Fig. 1A, artifacts related to respiration in ECG and EEG recordings are shown in conjunction with tracheal pressure. Highpass filtered artifact size was highly correlated with peak inspiratory pressure ($r^2=0.85$; $n=14$ animals). The size of the artifact itself cannot discriminate between effective breaths and attempts to breathe. The specific biomarker is the upward trend in artifact size as a marker for increasing effort during airway obstruction.

Bradyarrhythmia is present in most patients [Ryvlin et al.] and animals. [Nakase et al.; Hotta et al. *Epilepsia* 50: 923, 2009]. An abrupt change in the ECG RR interval variability (SDNN; ECG and filtered ECG) and that the normal lengthening of the RR interval during inspiration could be reversed during the late occlusion period. This pattern represents a second biomarker for airway obstruction, even with short time samples. Abnormally short RR intervals associated with inspiration occurred in no animals at baseline, 4/16 animals during early occlusion, and 15/16 during late occlusion.

Figs. 1A-1E show a demonstration of inspiration associated artifacts and changes in RR interval length during obstruction as biomarkers for obstructive apnea.

Fig. 1A shows artifacts enhanced in EEG and ECG by highpass filtering. Arrows indicate last breath attempt.

Fig. 1B shows correlations of ECG and EEG artifacts with peak inspiratory pressure (PIP).

Fig. 1C shows a plot of RR over time (black), PIP during obstruction (blue) and PIP peak markers (red). RR variance increases late in the occlusion. Relative minima in RR intervals are ONLY shorter than baseline during extreme inspiratory effort. Arrows point to the artifact or RR plot minimum for the breath just before a missed breath. Heavy black line at the bottom of the graph is the time shown in the inset.

Fig. 1D shows the standard deviation of the RR intervals ($n=16$ animals).

Fig. 1E shows plots of RR intervals as function of the time relative to the PIP ($n=16$ animals). Fitted curves for baseline and onset use right ordinate. Note the reverse relation of RR to inspiratory peak.

EXAMPLE 2

The spread of seizure activity over the principal motor nerve of the larynx, RLN, was studied in one set of experiments aimed at characterizing RLN activity during normal quiet breathing

- 19 -

(baseline) and during seizure activity induced by kainic acid. A tracheal opening or T-shaped tracheal tube that preserved RLN bilaterally was used to protect animals from laryngospasm. In animals with a tracheal tube, periods of complete glottic closure could be studied with laryngoscopy without concern about oxygen desaturation. RLN recordings were also made
5 during other experiments with the goal of capturing RLN activity during specific events such as periods of central and obstructive apnea. EEG, multi-unit RLN activity, and ECG were recorded in all animals. Laryngoscopy was performed at intervals during experiments.

The impact of laryngospasm and seizure activity on ventilation was assessed with head- out plethysmography in a second set of experiments. One group of animals was intubated with an
10 endotracheal tube prior to seizure induction and these animals were compared with non-intubated animals. The non-intubated animals comprised two subgroups: one with no treatment other than kainic acid to induce seizures, and a second with bilateral superior laryngeal nerve transection to prevent reflex laryngospasm performed in the pre-seizure condition.

Seizure activity was associated with increases in RLN activity and abnormal, high frequency
15 movements of vocal folds. Within a single seizure, RLN activity progressively increased, with the highest levels of activity most commonly observed near the end of the seizure. The full pattern of an RLN activity increase during a single seizure and its decrease to baseline at the end of the seizure could be observed when the airway was protected by a tracheal tube or window (Fig. 2). Laryngospasm during seizure activity had a significant impact on respiration

Fig. 2 shows extreme increases in RLN activity during a seizure. Segments from a complete
20 seizure are shown with normal respiratory bursting on RLN (top left, even lines) giving way to significantly increased firing (right side of top trace with maximum on right side of second trace) with eventual firing reductions (bottom trace). EEG is shown on odd lines. Estimates of seizure onset and offset (based on changes in low frequency activity and spiking) are marked with
25 arrows. In these animals, the airway was protected with a tracheal implant or opening cut through the tracheal cartilage so that the entire profile of RLN activity during individual seizures might be captured.

During normal tidal breathing under urethane anesthesia, the early expiratory peak in rats resembles human breathing (Arito et al., 1997). Three of 14 non-intubated rats and 1 of 6
30 intubated rats had seizure activity mainly characterized by low frequency, repetitive gasping breaths and were not included in the summary data. Plethysmograph recordings were taken before and after SLN lesions in this subgroup, and before and after intubation in intubated animals. None of the measured parameters showed a difference due to SLN lesion or intubation.

- 20 -

Pre-seizure values used for comparison with seizure values were the baseline condition for KA-only animals, the post-intubation condition for intubated animals, and the post-lesion condition for SLN lesioned animals. There were no differences between the two subgroups of non-intubated rats and their measures were pooled for statistics except when these two groups were compared with each other. Examples of flow-volume loops for non-intubated and intubated rats are shown in Fig. 3.

Fig. 3 shows plethysmography during kainic acid-induced seizure activity. Head plethysmography examples from one non-intubated (panels A1, C1) and one intubated (panels B1, D1) rat. The pre-seizure baseline condition for each animal is shown in the top row (panels A1, B1) and the corresponding seizure-associated condition is shown below (panels C1, D1). For each panel, 5 minutes' worth of continuous breathing that was analyzed to produce the flow-volume loops in each case. The upper horizontal red line on each flow-volume graph is the mean peak expiratory flow, the lower horizontal red line is the mean peak inspiratory flow, and the vertical red line is the mean tidal volume. Several key features are evident: 1) tidal volumes during seizure activity are lower for both animals; 2) the variability of breath flows and volumes during seizures are increased for both animals; 3) the ratio of peak inspiratory flow to peak expiratory flow is decreased for the non-intubated rat and increased for the intubated rat (calculated average shown at the upper right of each flow-volume graph).

Seizure activity was associated with large increases in respiratory rate in all remaining rats (11 non-intubated and 5 intubated), irrespective of treatment, from mean pre-seizure rates of 85 ± 11 and 98 ± 17 breaths/min for non-intubated and intubated rats, respectively to seizure associated rates of 371 ± 54 and 295 ± 43 breaths/min. Increases were significant ($p < 0.0001$) after Scheffe post hoc correction of multi-variate ANOVA. Pre-seizure mean rates of 89 and 81 breaths/min were observed in the 5 KA-only rats and the 6 non-intubated SLN lesioned animals, with seizure-associated mean rates of 371 breaths/min for both groups ($p < 0.0001$ for both comparisons).

Other details are given in Table 1, which shows a summary of first and second order plethysmography variables. The full set of plethysmography variables measured are shown with details for baseline, post manipulation (intubation or SLN lesion) and during seizure activity. The manipulations (intubation or SLN lesion) did not change baseline values significantly for any parameter, but seizure activity changed many parameters related to durations and volumes in all animals. The principal measure to discriminate between non-intubated and intubated animals

- 21 -

was the ratio of inspiratory peak flow to expiratory peak flow. Scheffe post-hoc corrections applied to one-way ANOVAs. A p value of 0 is used to indicate $p < 0.0001$.

Tidal volume decreased significantly in the non-intubated rats. Mean pre-seizure tidal volumes of 1.50 ± 0.36 ml/breath decreased to 0.46 ± 0.14 ml/breath ($p < 0.0001$). Subgroup tidal volumes were each significantly decreased: 1.2 to 0.46, $p = 0.008$ for KA-only rats and 1.7 to 0.46, $p < 0.0001$ for SLN lesioned rats). The difference in pre-seizure (1.03 ± 0.69 ml/breath) vs. seizure (0.53 ± 0.26 ml/breath) tidal volume in intubated animals did not reach statistical significance.

Given that ventilation rates increased approximately 3-fold and tidal volumes decreased approximately 3-fold during seizure activity, the average minute ventilation during seizure activity did not differ significantly from baseline, but tended toward lower values. Mean pre-seizure values of 124.8 ± 27.3 and 124.2 ± 61.8 ml/min were associated with mean seizure values of 100.8 ± 35.7 and 93.2 ± 42.3 ml/min (NS, NS) for non-intubated and intubated rats. Only the SLN lesioned subgroup showed a significant decrease in minute ventilation from 138.8 ± 13.2 to 106 ± 22.4 ml/min ($p < 0.0001$). Mean pre-seizure and seizure values for the KA-only rats were not significantly different (108.0 ± 25.0 vs. 94.4 ± 49.7 ml/min; NS).

The most dramatic differences were seen in the ratio of peak flow during inspiration to peak flow during expiration. This parameter is used to identify upper airway obstruction. Normally, this ratio is ≥ 1 , and values < 1 are indicative of extrathoracic (e.g. upper airway) obstruction (Blitzer and Meyer, 2006; Miller et al., 1987). Mean pre-seizure ratios were 1.04 ± 0.25 for non-intubated rats and 1.02 ± 0.10 for intubated rats. These values changed in opposite directions for intubated (increasing to 1.56 ± 0.38 ; $p = 0.011$) and non-intubated rats (decreasing to 0.52 ± 0.32 ; $p < 0.001$). The individual subgroups of non-intubated animals each showed decreases in the ratio of peak flows during inspiration and expiration: 0.95 to 0.60 for KA-only rats (NS) and 1.11 to 0.46 for SLN lesioned rats ($p = 0.001$). Whereas the decrease in $PF(i)/PF(e)$ is consistent with partial airway obstruction from laryngospasm, the increase in $PF(i)/PF(e)$ is clearly not from one of the typical causes of variable intrathoracic obstruction. Since there was no obstruction in the intubated animals, the flow-volume characteristics of the intubated animals reflect seizure-induced disordered ventilation without contribution from airway narrowing. If this is true, the decreased $PF(i)/PF(e)$ seen in non-intubated rats should be considered an underestimate, more properly compared with the intubated rats' seizure condition than with their own pre-seizure condition.

- 22 -

Values are summarized in Table 2, which shows summary statistics from plethysmography data. To compensate for multiple ANOVAs, a difference score (seizure condition minus pre-seizure condition) was computer for each animal on the 4 variables derived from the plethysmograph (respiratory rate, tidal volume, minute ventilation, and the ratio of inspiratory peak flow to expiratory peak flow). A 2-tailed Mann-Whitney test was conducted of the difference of distribution of these change- scores between intubated and pooled non-intubated study arms. Bootstrapping (20,000 replications) was used (SAS 9.4 Proc Multtest) to arrive at corrected p-values for the four measures, based on independent samples 2-tailed t-tests performed on ranked scores.

Figs. 4A and 4B show irregular vocal fold movement during seizure activity. Laryngoscopy during seizure activity revealed “shaking” movements of the arytenoid cartilages consistent with the findings of partial obstruction from plethysmography and abnormal RLN activity. In analyses of video recordings of laryngeal vocal fold and arytenoid cartilage movements, the highly correlated movements of the left and right arytenoid cartilages uncouple partially from an average Pearson correlation of -0.95 ± 0.04 to -0.79 ± 0.11 ($n=10$; $p=0.0007$), as shown in Fig. 4A. Frame-by-frame analysis of vocal fold and arytenoid cartilage position during video recordings of laryngoscopy show the typical coordinated abduction and adduction (periodic low frequency trace of upper graph of Fig. 4A) of the vocal folds during respiration. The position of the left arytenoid cartilage relative to the midline is shown as an upward deflection in the top graph, and the right arytenoid cartilage position is shown as a downward deflection. The correlation is high (0.98). During seizure activity (high frequency trace), the total displacement is less, the frequency is higher, and the correlation is decreased (0.75).

The distributions of time in quintiles of the peak-to-peak glottic opening (measured at baseline) is shown in Fig. 4B. The distribution of times across degrees of glottic opening (bin sizes = 20% of minimum to maximum opening in the baseline condition) were shifted toward larger openings, but with less variation in glottic opening. In fact, the average total normalized glottic opening over 10 seconds was larger during seizure activity than during baseline (0.36 ± 0.03 baseline, 0.47 ± 0.06 seizure; $p=0.00005$). At baseline (squares), the largest fraction of time is in the closed position, with rapid cycling through open angles. The distribution of times for a sine wave are shown for reference (dotted line). During seizure activity, the profile is changed significantly (circles) with a larger fraction of time in relatively open states, which would seem to mitigate the relatively stationary opening. Data are shown as means $\pm$ standard deviations.

- 23 -

Whereas clear evidence of partial airway obstruction due to laryngospasm was routinely observed, the modest decreases in minute ventilation suggested that respiratory derangements during seizures were adequately compensated. However, complete glottic closure (confirmed with laryngoscopy) occurred in a subset of non-intubated animals during discrete seizures in association with the largest increases in RLN activity, and cessation of airflow was followed in all animals within tens of seconds with ST segment elevations in ECG, bradycardia, and eventually death. Complete obstructive apnea occurred in 7 of 11 non-intubated and 0 of 5 intubated rats ($p=0.03$, Fisher exact test, two-tailed). All 7 animals died. The start of the obstructive apneic period was taken as the time from the point at which peak-to-peak airflow reached $<10\%$ of the pre-apneic peak-to-peak airflow, and the endpoint was the time at which the recording was stopped and the animal removed from the plethysmography chamber with evidence of severe bradycardia on ECG that, upon removal from the plethysmography chamber, was associated with apparent cardiopulmonary arrest. Only when an artificial airway was present was a period of complete glottic closure due to laryngospasm seen to terminate on its own with a reversion to the normal pattern of opening and closing with each breath.

Fig. 5 shows obstructive and central apnea during seizures. The top panel illustrates an episode of obstructive apnea due to laryngospasm with hypoxic cardiac arrhythmia. Each set of traces consists of plethysmography (top); ECG (middle); EEG (bottom). The obstructive apnea develops as a rapid, but continuous (several seconds) reduction in the amount of air per breath until that amount is negligible. At the time indicated as complete obstruction (confirmed by simultaneous laryngoscopy - single frames shown at the right), the ECG develops clear bradyarrhythmia with ST segment elevation from hypoxemia develops. The recording is taken from the end of a seizure; seizure activity is present from the beginning of the illustrated data and an estimate of seizure offset (based on a complete flat-lining of EEG) is marked by an arrow. Episodes of central apnea, by contrast, were characterized by an abrupt cessation of breathing and air flow, but the vocal folds arrested in an open position (video frame at right). There were no cardiac derangements over the same time period. The entire record, taken from the middle of a seizure, displays seizure activity.

On plethysmography records, airflow declined rapidly to zero or near zero flow (Fig. 5, top). In every case, ST-segment elevation on ECG recordings was clear evidence of hypoxemia. Laryngoscopy revealed complete glottic closure. The shortest duration period of obstructive apnea to produce apparent cardiopulmonary arrest was 56 seconds. RLN activity recorded with laryngoscopic confirmation of glottic closure ($n=2$) showed intense firing associated with the

- 24 -

laryngospasm and ECG evidence of hypoxia (Fig. 5, top). The occurrence of laryngospasm in SLN-lesioned animals is further evidence that laryngospasm was not mediated by pharyngeal/laryngeal reflexes that might have been activated by the laryngoscope or salivation.

Fig. 6 shows recurrent laryngeal nerve activity during obstructive and central apnea. RLN firing (middle trace of each panel) during obstructive apnea (top panel) and central apnea (bottom panel) show that the RLN is active during both types of apnea. The RLN carries motor output for both laryngeal abductors and adductors. The multi-unit recordings do not permit discrimination of nerve activity for abductors or adductors, but adduction dominates during obstructive apnea and abduction dominates during central apnea. Video frames are shown to the right. Also shown to the right are three ECG sweeps for each type of apnea to illustrate the pronounced ST segment elevation and slowing during obstructive apnea and the uniform PQRST complexes during central apnea. The recording illustrating obstructive apnea is taken from the end of a seizure; seizure activity is present from the beginning of the illustrated data and an estimate of seizure offset (based on a complete flat-lining of EEG) is marked by an arrow.

In contrast to systemic impact of obstructive apnea, periods of central apnea, characterized by an abrupt cessation of breathing effort, a completely open glottis, moderate RLN firing, and no air flow on plethysmography, were never associated with ST segment elevation in ECG or any other evidence that these episodes might be life threatening (Fig. 5, bottom and Fig. 6, bottom; Table 3).

Table 3 shows contrasts between obstructive apnea and central apnea. Details of obstructive and central apneic periods captured in non-intubated and intubated rats. Obstructive apnea appeared only in non-intubated rats, a difference that was significant ($p=0.034$). Central apneic periods averaged durations < 10 seconds, but some periods exceeded 30 seconds in duration. To compare the impact of apnea of either type on cardiac activity, HR and the presence or absence of ST segment elevation were compared over equivalent 10 second periods from the onset of apnea based on plethysmography records. ST segment changes were only seen during obstructive apnea periods. Taking the minimum HR over this period in comparison with baseline, both obstructive and central apneic periods were associated with significant bradycardia, but the changes associated with obstructive apnea were greater. All comparisons were two-tailed unpaired t-tests.

As further evidence that the glottic closure was active and not passive (e.g. resembling vocal fold paralysis (Mor et al., 2014)), plethysmography was performed, and recorded vocal fold motion in an animal whose right vocal fold was paralyzed by RLN damage (Fig. 7, hemiparetic).

- 25 -

During a seizure-induced period of obstructive apnea, the ECG shows ST-segment elevation and the plethysmograph shows an absence of air movement. The force of contraction of the left vocal fold actually pushed the arytenoid cartilage across the midline in the absence of resistance from the right vocal fold.

5 Fig. 7 also shows a demonstration of the force of contraction during laryngospasm. In this example, the normal open and closed states of the arytenoid cartilages are illustrated in the baseline panel (left) together with plethysmography, ECG, and EEG records taken simultaneously. The tick marks on the plethysmography records indicate the time of the video snapshots. Note that the glottis is not completely closed, even at the minimum of arytenoid
10 excursions from the midline. In the center panel, the right vocal fold was paralyzed by crushing the right RLN to cause hemiparesis. Breathing is changed from regular large breaths to more frequent smaller breaths mixed with large gasps. The far right panel shows a segment taken from the same rat during seizure induced laryngospasm sufficient to produce obstructive apnea. The glottis is completely closed, but note how left side of the larynx actually crosses the midline
15 when not opposed by an active right side (white arrow in video snapshot). Also note the ST-segment elevations are prominent (asterisk on ECG trace) in contrast with the other two states. (Calibrations: 0.5 sec, 0.25 ml (pleth), 0.5 mV (ECG), and 0.1 mV (EEG)).

The lethality of obstructive apnea periods is contrasted with the minimal impact of central apnea periods in the same animals. That these transient periods of central apnea are separate
20 from the central apnea that characterizes respiratory arrest. Periods of central apnea were defined by an abrupt cessation of breathing for periods ≥ 1 second as evidenced in plethysmography records. These were recorded during seizure activity in animals of all groups with no differences in the frequency or duration of central apneic periods between groups. No central apneic periods were ever seen in baseline, pre-seizure/post-intubation, or pre-
25 seizure/post-SLN transection conditions. Three of 6 KA-only animals showed central apneic periods, compared with 3/5 SLN-lesioned animals, and 5/5 intubated animals. Central apneic periods as long as 33 seconds were recorded. The mean durations and counts of central apneic periods ≥ 1 s, and the subset of periods whose durations were ≥ 5 s are detailed in Table 3.

Two findings highlight the contrast between obstructive and central apnea. First, on
30 laryngoscopy during central apneic periods, the vocal folds were abducted and immobile and held the glottis in a completely open configuration for the entirety of the apneic period (Figs. 5, 6). The open state of the larynx is an active state, as shown by RLN activity during central apneic periods. Second, bradycardia developed to a much greater extent, plus ST-segment elevation

- 26 -

was prominent, during periods of obstructive apnea, but not central apnea. While it is true that the obstructive apnea periods lasted longer than central apnea periods (all central apnea periods ended spontaneously with a return to pre-apneic respiratory patterns), at the same time from apnea onset, only obstructive apnea impacted cardiac function. Taking all central apneic periods of 15 seconds or greater from all groups into a single pool (n=9 apneic periods from 6 animals), the change in heart rate within the time window of 5-15 seconds was examined for comparison with the mean heart rate pre-apnea. The mean and minimum heart rate measures during the 5-15 second time window of obstructive apnea were significantly decreased compared to pre-apnea rates. For central apneic periods, the minimum heart rate during 5-15 seconds was significantly decreased, but not the mean rate for the 10 second epoch. In comparing the relative changes, heart rate decreases during obstructive apnea (-31.4 ± 13.9 % change, n=7) were significantly greater than central apnea (-17.3 ± 9.7 % change, n=9) over the same time frames (Table 3). The average minimum heart rate for periods of obstructive apnea before stopping the recordings was 0.86 ± 0.38 beats/s (down from > 6 beats/s at baseline).

A series of experiments were conducted in which a controlled complete occlusion of the airway was used to study response kinetics without the uncertainty of when complete obstruction would occur during seizure activity. A T-shaped tracheal tube was implanted after dissecting the RLN free bilaterally. This enabled securing the tracheal tube in place without disturbing normal laryngeal function. A pressure transducer on the tracheal tube sidearm recorded forces developed during either normal breathing with the tracheal tube open to the atmosphere or during complete closure of the open port with an airtight cap. Complete obstruction of the airway was performed for 100 seconds or until 20 s after respiratory arrest occurred, whichever was earlier. In addition to tracheal sidearm pressures, ECG and pulse oximetry were recorded continuously. In subsets of animals, echocardiography and/or continuous arterial blood pressure monitoring were performed.

During occlusion, respiratory effort to inspire progressively increased, then ceased, usually in less than 1 minute (60.4 ± 24.0 s; median = 54.4 s; n=16). Respiratory arrest was associated with cardiac dilatation and asystole, an increase of systemic blood pressure (which collapsed without resuscitation), and laryngospasm sufficient for complete glottic closure. This is a type of central apnea that differs from the central apneic episodes reported earlier that were associated with an actively open airway. The LV diastolic cavity size became dilated by about 40% (0.47 ± 0.07 at baseline to 0.64 ± 0.22 cm 10 sec after respiratory arrest) and the end systolic LV cavity size

- 27 -

became dilated by nearly 300% (0.12 ± 0.03 at baseline and 0.44 ± 0.23 cm 10 seconds after respiratory arrest). The LV ejection fraction fell from 94 ± 2 to 49 ± 23 percent.

An example experiment is illustrated in Fig. 7 and the cardiac and respiratory function parameters are summarized in Figs. 8 and 9, which show echocardiography during controlled airway occlusion. Fig. 8 shows ECG, pulse oximetry, airway pressure transducer, and arterial blood pressure records during a 100 second occlusion of the trachea (onset and end marked with arrows). The development of bradyarrhythmia and the progressive inspiratory effort are clearly visible. The inspiratory effort is sufficient to significantly impact blood flow as evidenced by the larger pulse oximetry waves associated with each attempt to breathe. Fig. 9 shows a series of M-mode echocardiogram panels, each representing a respective 2-second period which has a reference number corresponding to the markings in the ECG trace of Fig. 8. Normal cardiac function is visible in the pre- occlusion record (panel 0 of Fig. 9). Panels 1-6 of Fig. 9 occur at points during the period of occlusion and show rhythm abnormalities and progressive left ventricular dilation. By the time respiration has arrested (echo panel 5 of Fig. 9), the heart is nearly akinetic. The recovery panel shows the abrupt return of cardiac performance after the airway obstruction has been removed and breathing has recovered. Major ticks on each plot in top panel: ECG = 0.25 mV; pulse ox = 5% variation (high pass filtered); airway transducer = 25 mmHg; BP = 10 mm Hg.

EXAMPLE 3

Fig. 10 shows results of a pilot human trial showing the use of biomarker 1 (the increased peak-to-peak amplitude of an ECG recording's background activity, which is due to increase thoracic muscular EMG getting included in the ECG signal) to detect obstructive apnea. The preliminary human subject data shows that biomarker 1 appears in a simple setting where patients try to inspire by drawing air out of closed 500 ml container. Significant increases in ECG background amplitude relative to QRS amplitude (simple ratio of peak-to-peak ECG signal to the peak-to-peak amplitude of the QRS complex) occur during the inspiratory effort.

This demonstrates that biomarker 1 has utility in any condition where EMG associated with inspiratory effort can be increased.

In Fig. 10, a statistical analysis of the results showed:

ANOVA: $F(1.487, 43.13) = 22.42$ $P < 0.0001$

Multiple comparisons:

PRE vs. DUR $p = 0.0001$

PRE vs. POST $p = 0.0128$

- 28 -

EXAMPLE 4

Tracheal tubes were placed in four rats, and strong seizure activity induced with kainic acid.

In three rats, systemic variables to describe the sequence of events leading to death were

monitored. During the period continuous seizure activity (status epilepticus), shallow, irregular

breathing was mixed with gasping breaths that occurred at a rate of 1/s, but dropped abruptly to

1/15 s before apparently stopping completely. Although the airway was completely open,

oxygen saturations of 54 or 77% (no data for 3rd rat) preceded the transition to very slow or

arrested breathing. The rate of change of oxygen saturation over time was well fitted with a

straight line (slope = -0.07 ± 0.05 pulse oximetry percentage points per second, $R^2 = 0.93 \pm$

0.04). From these values, an average 10% drop in oxygen saturation took 135 seconds (2.25

minutes) – compared with times of <10 seconds after onset of laryngospasm- induced obstructive

apnea or controlled occlusion. Whereas these animals demonstrated that, during periods of

sustained seizure activity, very low oxygen saturations and death could occur with an intact

airway, the times for desaturation were so long that this mechanism is unlikely to be the principal

mechanism for desaturation during discrete seizures. Rather, this mechanism is likely a distinct

feature of status epilepticus.

Fig. 11 shows a summary of cardiac and respiratory parameters during controlled airway

occlusion. Changes in heart rate derived from ECG, arterial oxygen saturation based on pulse

oximetry, respiratory rate and peak inspiratory pressure derived from a pressure transducer on

the sidearm of a tracheal implant, and left ventricular cavity size and ejection fraction derived

from echocardiography. A pre-occlusion baseline point is compared with three time points

during controlled airway occlusion (15 s after onset, at the time of respiratory arrest, and 10 s

after respiratory arrest), and recovery (60 s after the end of resuscitation efforts). Each point is

shown as its mean and standard deviation. Obstructed animals (squares) are also compared with

unobstructed control animals (circles) for some measures. Changes in respiratory parameters and

oxygen saturation occur, in general, earlier than changes in cardiac parameters as evidenced by

statistically significant decreases in these parameters by 15 s after the onset of airway occlusion.

By the time of respiratory arrest, left ventricular performance is significantly impaired as

illustrated with significant dilatation (enlarged end systolic dimension) and decreased ejection

fraction. Units for plots: HR (beats/s), oxygen saturation (% saturation), respiratory rate

(breaths/s), peak inspiratory pressure (mmHg/100), ventricular cavity size (cm), and ejection

fraction (% diastolic volume ejected during systole).

- 29 -

Unlike laryngospasm-mediated obstruction where the vocal folds were continuously adducted, during the period of obstruction, each attempted inspiration was associated with an opening and closing of the airway by vocal fold movements such that the degree of opening increased as the inspiratory effort increased. Each glottic opening was followed by a complete closure of the airway due to fully apposed arytenoid cartilages and vocal folds. The maximal opening angle during the last breath attempt was $56.7 \pm 5.3^\circ$ compared to baseline values of $27.6 \pm 4.6^\circ$ ($p < 0.00001$). After the last breath attempt, the airway stayed in this closed position for an additional 20-60 seconds before normal breathing and vocal fold motion resumed after resuscitation or a small glottic opening became evident when the vocal folds appeared to relax in animals that were not resuscitated.

From the point of the last apparent breath, a minimum in heart rate was reached in 30, 70, or 140 seconds. In two animals, laryngospasm was recorded only after the appearance of bradycardia because the larynx was not being continuously monitored. For the third rat, first evidence of laryngospasm was captured on video. This showed that breathing appeared to stop 18 seconds before laryngospasm and cessation of seizure activity as evidenced by flattening of the EEG. Whereas hypoxia-induced laryngospasm such as that described in the controlled occlusion experiments might account for the laryngospasm observed in the first two rats, laryngospasm in the third rat was uncoupled from the respiratory pattern and apparently still driven by seizure activity.

The key findings of these studies are that: 1) seizure activity causes large increases in RLN activity; 2) seizure activity changes breathing frequency, amplitude, variability, and can cause central apnea; 3) seizure activity causes laryngospasm that can result in partial or complete airway occlusion (obstructive apnea); 4) only obstructive apnea was associated with rapid, severe arterial oxygen desaturation, bradycardia, respiratory arrest, and death; 5) hypoxemia itself can cause laryngospasm, significantly prolonging complete airway closure; and 6) sudden death is the result of respiratory arrest during airway obstruction and nearly simultaneous left-ventricle dilatation and asystole. From this set of findings, it is concluded that sudden death in any animal or person experiencing a seizure can be the result of seizure-induced laryngospasm sufficient to cause obstructive apnea, which leads to respiratory arrest and cardiac asystole within tens of seconds, and which can only be reversed by cardiopulmonary resuscitation (i.e. spontaneous recovery is highly unlikely).

Seizures clearly disrupt normal breathing. Respiratory frequency, tidal volume, and cycle variability were all changed by seizure activity. More severe outcomes were marked by periods

- 30 -

of no airflow at all, either because the drive to breathe ceased while the glottis was fully open (central apnea) or because the glottis was closed due to laryngospasm (obstructive apnea). The most significant impact on oxygen status and cardiac and respiratory function was from obstructive apnea secondary to seizure-induced laryngospasm. A straightforward interpretation of these observations is a spread of seizure activity along the pathway from subiculum to paraventricular nucleus (PVN) of the hypothalamus (Canteras and Swanson, 1992) and from PVN to medullary regions (e.g. (Geerling et al., 2010)), where it impacts medullary autonomic nuclei, respiratory centers, and laryngeal motor neurons.

What is it about seizure-induced obstructive apnea that resulted in such rapid and severe cardiopulmonary dysfunction? The lack of airflow could not have been the problem since the periods of central apnea did not cause the same deterioration. The remarkable feature of the obstructive apneas was that the airway was completely shut. The forces of vocal fold contractions during seizure-induced laryngospasm were illustrated by the fact that an active vocal fold actually crossed the midline when it was not opposed by a paralyzed vocal fold and the fact that the usual opening of the vocal folds during attempts to gasp did not occur. By contrast, the vocal folds were always in a completely open position during periods of central apnea. It is conceivable that the occurrence of laryngospasm merely reflected a level of seizure activity that caused cardiopulmonary dysfunction by a mechanism independent of obstructive apnea. However, when the airway was manually occluded by closing a tracheal tube in rats that had not been treated with kainate and were not undergoing seizures, the same sequence and time course of events was observed: oxygen desaturation, bradycardia, and ST-segment elevation within seconds, respiratory arrest and serious cardiac mechanical failure within about one minute, and cardiac arrest within several minutes. The combination of these findings indicates that it is the airway occlusion that triggers cardiopulmonary collapse and death.

A major difference between central and obstructive apnea relates to the intense autonomic response that comes during attempts to breathe against a closed airway or during asphyxiation (e.g. (Brostrom et al., 2007; Hotta et al., 2009; Weiss et al., 2015)), but does not occur in the absence of a drive to breathe. Breath holding can last for long times without detriment; the current world record in humans exceeds 11 minutes, or over 22 minutes after hyperventilation with pure oxygen (Association Internationale pour le Développement de l'Apnée; www.aidainternational.org/). It involves a voluntary reduction of the drive to breath, but does not require closing the glottis (Donzelli and Brady, 2004; Mendelsohn and Martin, 1993) and does not significantly activate the autonomic nervous system. Seizure-induced central apneas are

- 31 -

generally harmless because they induce only a minimal autonomic and systemic response in the absence of a drive to breathe. Seizure-induced obstructive apneas, in contrast, are deadly because the attempt to breathe against a closed airway triggers a strong autonomic co-activation, on top of an already raised autonomic tone due to the seizures themselves, that ultimately results in
5 cardiopulmonary collapse.

Given the complexity and interdependence of the cardiac, respiratory, and nervous systems, the question arises whether laryngospasm is both necessary and sufficient for sudden death. First, seizure-induced laryngospasm is not reflex-driven by salivation or other pharyngeal stimuli because a subgroup of non-intubated rats had bilateral superior- laryngeal-nerve lesions that
10 would abolish the afferent limb of a reflex to drive laryngospasm. All of the deaths observed during the plethysmography experiments occurred with a sequence of seizure-induced laryngospasm followed by respiratory and then cardiac arrest with exactly the same temporal profile observed during the controlled occlusion of tracheal implants. Therefore, closing the airway by itself crosses a critical threshold and that seizure-induced laryngospasm is sufficient
15 for sudden death.

The MORTEMUS heart rate data show that 9/10 patients experienced the largest drop in heart rate during the period of apparent respiration at the end of the seizure (Figure 3 of Ryvlin et al., 2013) and before the onset of terminal apnea. The timing of the sharp drop in heart rate in the present rat experiments corresponds to a point late in the period of obstruction, after the seizure
20 would have been terminated (Stewart, 2008), but before the point of respiratory arrest, which are believed to correspond to the onset of terminal apnea in the MORTEMUS study (Ryvlin et al., 2013). It is not only possible, but probable that the SUDEP cases of the MORTEMUS study experienced obstructive apnea as evidenced by the same terminal sequence of events leading to respiratory arrest and death as found for rats.

Laryngospasm may contribute to sudden death even in cases when it is not the initial trigger. In the manual airway occlusion experiments, laryngospasm was observed after respiratory arrest. This complicates the interpretation of clinical case reports since the presence of laryngospasm postictally may indicate either laryngospasm-mediated hypoxia or hypoxia-mediated
25 laryngospasm. More ominously, whether laryngospasm starts the desaturation or occurs after desaturation, it guarantees that death occurs unless cardiopulmonary resuscitation is initiated
30 shortly after respiratory arrest (when there is no effort to breathe and the heart is severely dilated).

A sequence of events is defined that links seizures to sudden death. In particular, seizure-induced laryngospasm resulted in cessation of airflow, followed within tens of seconds by ST-

- 32 -

segment elevation, bradycardia, and respiratory arrest. These data were obtained in an established animal model for seizure experiments (urethane- anesthetized rats treated with kainic acid), not in humans, but demonstrate the utility of this rat model for studying laryngospasm and obstructive apnea.

5 Figs. 12 and 13 show prior art ECG acquisition circuits. See www.electro-tech-online.com/attachments/untitled-gif.26911/; www.electro-tech-online.com/attachments/ecg-circuit-png.26416/; and gasstationwithoutpumps.files.wordpress.com/2012/08/dobrev-amp.jpg, each of which is expressly incorporated herein by reference in its entirety.

10 Figs. 14, 15 and 16 show aspects of a prior art ECG analog acquisition and wireless transmitter system, See, Fen Miao, Yayu Cheng, Yi He, Qingyun He and Ye Li, "A Wearable Context-Aware ECG Monitoring System Integrated with Built-in Kinematic Sensors of the Smartphone", *Sensors* 2015, 15(5), 11465-11484; doi:10.3390/s150511465, www.mdpi.com/1424-8220/15/5/11465/htm, which is expressly incorporated herein by reference. In its entirety.

15 The block diagram of a proposed ECG monitoring system combined a wearable ECG acquisition sensor with a smartphone is shown in Figure 14. The ECG sensor follows the YY1139-2000 standard (a pharmaceutical industry standard of China for single and multichannel electrodiagraph, which is evolved from EC13 national standard). In the ECG acquisition sensor, signal is amplified and filtered by a single chip of AFE module, then in MCU module the analog
20 signal from AFE is converted to digital signal. After processed with compression algorithm, the digital signal is recorded in SD card or transmitted to smartphone for real-time display. Meanwhile, a USB port is equipped in the device for transmitting the signals which have been saved in the SD card to personal computers and then to the cloud platform for further analysis. The ECG signals transmitted to smartphone are real-time displayed on screen, with a brief report
25 provided from the automatic analysis approach in the software or professional advices provided from the remote server. The built-in kinematic sensors of the smartphone are used to recognize the individual's physical activity and thus help to improve the diagnosis accuracy for detecting abnormal patterns.

30 The block diagram of traditional implementation of ECG acquisition device is presented in Fig. 15, in which the circuit consists of a traditional instrument amplifier and Sallen-Key or Nyquist low pass filter, and some external function circuits for realistic ECG detection. The system employs various discrete components which occupy circuit board area.

- 33 -

Miao et al. propose an architecture using a fully custom, fully integrated, low power AFE, with all the function circuits integrated, as shown in Fig. 16 of the prior art, with an input/output buffer, full differential amplifier (DA) with high pass function, second Gm-C low pass filter, additional amplifying stage, DRL circuit, lead-off detecting circuit, fast restore function, and a power management module to provide a stable working voltage and current.

US 2016/0128209, expressly incorporated herein by reference in its entirety, discloses an exemplary hardware platform that can be used to implement the present technology, as shown in Figs. 17 and 18.

Referring to Fig. 17 of US 2016/0128209, the electronic device 100 can constitute at least one of: at least one AP (application processor) 910, a communication module 920, a SIM (subscriber identification module) card 924, a memory 930, a sensor module 940, an input device 950, a display 960 (e.g. the display device 13), an interface 970, an audio module 980, a camera module 991, a power management module 995, a battery 996, an indicator 997, and a motor 998. The AP 910 controls a plurality of hardware or software components connected to the AP 910 by driving an operating system or an application program, process various data including multimedia data, and perform calculations. The AP 910 can be embodied as, for example, a System on Chip (SoC). According to an embodiment, the AP 910 further includes a Graphic Processing Unit (GPU). The communication module 920 (e.g. the communication interface 160) can perform data transmission/reception in connection with communication with other electronic devices connected to the electronic device 100 via a network. According to one embodiment, the communication module 920 includes at least one of: a cellular module 921, a Wi-Fi module 923, a BT module 925, a GPS module 927, an NFC module 928, and a Radio Frequency (RF) module 929. The cellular module 921 provides a voice call, a video call, a text message service, or an Internet service through a communication network (for example, LTE, LTE-A, CDMA, WCDMA, UMTS, WiMax, GSM, 3G, 4G, 5G, or the like). Further, the cellular module 921 distinguishes and authenticates electronic devices within a communication network by using a subscriber identification module (for example, the SIM card 924). According to an embodiment, the cellular module 921 performs at least some of functions that the AP 910 provides. For example, the cellular module 921 can perform at least a part of a multimedia control function.

The cellular module 921 may include a Communication Processor (CP). Further, the cellular module 921 can be implemented by, for example, an SoC. Although components such as the cellular module 921 (e.g., the communication processor), the memory 930, or the power management module 995 are illustrated to be separate from the AP 910 in Fig. 17, the AP 910

- 34 -

can be implemented to include at least some of the above described components (e.g., the cellular module 921). The AP 910 or the cellular module 921 (for example, communication processor) can load a command or data received from at least one of a non-volatile memory and other components connected to each of them to a volatile memory and process the loaded
5 command or data. Further, the AP 910 or the cellular module 921 can store data received from or generated by at least one of the other components in a non-volatile memory.

Each of the Wi-Fi module 923, the BT module 925, the GPS module 927, and the NFC module 928 can include, for example, a processor for processing data transmitted/received through the corresponding module. In Fig. 17, the cellular module 921, the WiFi module 923, the
10 BT module 925, the GPS module 927, and the NFC module 928 are illustrated as blocks separated from each other, but, according to an embodiment, at least some (for example, two or more) of the cellular module 921, the WiFi module 923, the BT module 925, the GPS module 927, and the NFC module 928 can be included in one Integrated Chip (IC) or one IC package. For example, at least some (for example, a communication processor corresponding to the
15 cellular module 921 and a Wi-Fi processor corresponding to the Wi-Fi module 923) of the processors corresponding to the cellular module 921, the Wi-Fi module 923, the BT module 925, the GPS module 927, and the NFC module 928, respectively, can be implemented by a single SoC.

The RF module 929 transmits and receives data, for example, an RF signal. Although not
20 illustrated, the RF module 929 includes, for example, a transceiver, a Power Amplifier Module (PAM), a frequency filter, a Low Noise Amplifier (LNA), or the like. Further, the RF module 929 further includes a component for transmitting/receiving an electromagnetic wave in a free space during a radio communication, such as a conductor or a conducting wire. Although the cellular module 921, the Wi-Fi module 923, the BT module 925, the GPS module 927, and the
25 NFC module 928 are illustrated to share one RF module 929 in Fig. 17, at least one of the cellular module 921, the Wi-Fi module 923, the BT module 925, the GPS module 927, and the NFC module 928 transmits and receives RF signals through a separate RF module.

The SIM card 924 is a card including a subscriber identification module, and can be inserted into a slot formed in a particular portion of the electronic device. The SIM card 924 includes
30 unique identification information (for example, Integrated Circuit Card Identifier (ICCID)) or subscriber information (for example, International Mobile Subscriber Identity (IMSI)).

The memory 930 (for example, memory 130) includes an internal memory 932 or an external memory 934. The internal memory 932 includes at least one of a volatile memory (for example,

- 35 -

a Dynamic RAM (DRAM), a Static RAM (SRAM), a Synchronous Dynamic RAM (SDRAM), and the like) and a non-volatile memory (for example, a One Time Programmable ROM (OTPROM), a Programmable ROM (PROM), an Erasable and Programmable ROM (EPROM), an Electrically Erasable and Programmable ROM (EEPROM), a mask ROM, a flash ROM, a NAND flash memory, a NOR flash memory, and the like).

According to an embodiment, the internal memory 932 is a Solid State Drive (SSD). The external memory 934 can further include a flash drive, for example, a Compact Flash (CF), a Secure Digital (SD), a Micro Secure Digital (Micro-SD), a Mini Secure Digital (Mini-SD), an extreme Digital (xD), a memory stick or the like. The external memory 934 can be functionally connected to the electronic device 100 through various interfaces. According to an embodiment, the electronic device 100 further includes a storage device (or storage medium) such as a hard drive.

The sensor module 940 measures a physical quantity or detects an operation state of the electronic device 100, and converts the measured or detected information to an electronic signal.

The sensor module 940 includes, for example, at least one of a gesture sensor 940A, a gyro sensor 940B, an atmospheric pressure sensor 940C, a magnetic sensor 940D, an acceleration sensor 940E, a grip sensor 940F, a proximity sensor 940G, a color sensor 940H (for example, red, green, and blue (RGB) sensor), a biometric sensor 940I, a temperature/humidity sensor 940J, a luminance sensor 940K, and an Ultra Violet (UV) sensor 940M. Additionally or alternatively, the sensor module 940 includes, for example, an E-nose sensor (not illustrated), an ElectroMyoGraphy (EMG) sensor (not illustrated), an ElectroEncephaloGram (EEG) sensor (not illustrated), an ElectroCardioGram (ECG) sensor (not illustrated), an InfraRed (IR) sensor, an iris sensor (not illustrated), a fingerprint sensor (not illustrated) and the like. The sensor module 940 further includes a control circuit for controlling one or more sensors included therein.

The input device 950 includes a touch panel 952, a (digital) pen sensor 954, a key 956, or an ultrasonic input device 958. The touch panel 952 recognizes a touch input through at least one of, for example, a capacitive scheme, a resistive scheme, an infrared scheme, and an ultrasonic scheme. The touch panel 952 further includes a control circuit. The capacitive scheme touch panel recognizes physical contact or proximity. The touch panel 952 further includes a tactile layer. In this case, the touch panel 952 provides a tactile reaction to a user.

The (digital) pen sensor 954 can be embodied, for example, using a method identical or similar to a method of receiving a touch input of a user, or using a separate recognition sheet. The key 956 includes, for example, a physical button, an optical key or a keypad. The ultrasonic

- 36 -

input device 958 has an input tool, which generates ultrasonic signals, so that the electronic device 100 senses sound waves using the microphone 988 and identifies data, and is capable of wireless recognition. According to an embodiment, the electronic device 100 receives a user input from an external device (for example, computer or server) connected thereto by using the communication module 920.

The display 960 (e.g. the display device 13) includes a panel 962, a hologram device 964, or a projector 966. The panel 962 can be, for example, a Liquid Crystal Display (LCD), Active-Matrix Organic Light Emitting Diode (AM-OLED), or the like. The panel 962 can be embodied to be, for example, flexible, transparent, or wearable. The panel 962 can be also configured as one module together with the touch panel 952. The hologram 964 can show a stereoscopic image in the air by using interference of light. The projector 966 can project light onto a screen to display an image. For example, the screen can be located inside or outside the electronic device 100. According to one embodiment, the display 960 can further include a control circuit for controlling the panel 962, the hologram device 964, or the projector 966.

The interface 970 includes, for example, a High-Definition Multimedia Interface (HDMI) 972, a Universal Serial Bus (USB) 974, an optical interface 976, or a D-subminiature (D-sub) 978. Additionally or alternatively, the interface 970 includes, for example, a Mobile High-definition Link (MHL) interface, a Secure Digital (SD) card/Multi-Media Card (MMC) interface, or an Infrared Data Association (IrDA) standard interface.

The audio module 980 bi-directionally converts a sound and an electronic signal. At least some of the components of the audio module 980 can be included in the input/output interface. The audio module 980 processes voice information input or output through, for example, a speaker 982, a receiver 984, earphones 986, the microphone 988 or the like.

The camera module 991 is a device which can photograph an image and a dynamic image. According to an embodiment, the camera module 291 includes one or more image sensors (for example, a front sensor or a back sensor), a lens (not shown), an Image Signal Processor (ISP) (not shown) or a flash (not shown) (for example, LED or xenon lamp).

The power management module 995 manages power of the electronic device 100. Although not illustrated, the power management module 995 includes, for example, a Power Management Integrated Circuit (PMIC), a charger Integrated Circuit (IC), or a battery or fuel gauge. The PMIC can be mounted to, for example, an integrated circuit or an SoC semiconductor. Charging methods can be classified into a wired charging method and a wireless charging method. The charger IC charges a battery and prevents over voltage or over current from being flowed from a

- 37 -

charger. According to an embodiment, the charger IC includes a charger IC for at least one of the wired charging method and the wireless charging method. A magnetic resonance scheme, a magnetic induction scheme, or an electromagnetic scheme can be exemplified as the wireless charging method, and an additional circuit for wireless charging, such as a coil loop circuit, a resonance circuit, a rectifier circuit, and the like can be added. The battery fuel gauge measures, for example, a remaining quantity of the battery 996, or a voltage, a current, or a temperature during the charging. The battery 996 stores or generates electricity, and supplies power to the electronic device 100 using the stored or generated electricity. The battery 996 can include, for example, a rechargeable battery or a solar battery.

The indicator 997 indicates particular states (e.g., a booting state, a message state, a charging state, etc.) of the electronic device 100 or a part (e.g., the AP 910) of the electronic device 900. The motor 998 converts an electrical signal to a mechanical vibration. Although not illustrated, the electronic device 100 includes a processing unit (for example, GPU) for mobile TV support. The processing unit for supporting the mobile TV processes media data according to a standard of Digital Multimedia Broadcasting (DMB), Digital Video Broadcasting (DVB), media flow or the like.

The above described components of the electronic device according to various embodiments of the present disclosure can be formed of one or more components, and a name of a corresponding component element may be changed based on the type of electronic device. The electronic device according to the present disclosure may include one or more of the aforementioned components or may further include other additional components, or some of the aforementioned components may be omitted. Further, some of the components of the electronic device according to the various embodiments of the present disclosure may be combined to form a single entity, and thus, may equivalently execute functions of the corresponding elements prior to the combination.

The "module" used in various embodiments of the present disclosure may refer to, for example, a "unit" including one of hardware, software, and firmware, or a combination of two or more of the hardware, software, and firmware. The "module" may be interchangeable with a term, such as a unit, a set of logic, e.g., embodied in a non-transitory computer readable medium, a logical block, a component, or a circuit. The "module" may be a minimum unit of an integrated component element or a part thereof. The "module" may be a minimum unit for performing one or more functions or a part thereof. The "module" may be mechanically or electronically implemented. For example, the "module" according to various embodiments of the present

- 38 -

disclosure may include at least one of an Application-Specific Integrated Circuit (ASIC) chip, a Field-Programmable Gate Arrays (FPGAs), and a programmable-logic device for performing operations which have been known or are to be developed hereafter.

Fig. 18 of US 2016/0128209 is a diagram illustrating a network environment including an electronic device 100 which includes a bus 110, a processor 120, a memory 130, an input/output interface 140, a display 150, a communication interface 160, and an application operation module 170. The bus 110 is a circuit that connects the above-described components with each other and to transfer communication (for example, control messages) between the above-described components. For example, the processor 120 can receive instructions from the
5 aforementioned other elements (e.g., the memory 130, the input/output interface 140, the display 150, the communication interface 160, and the application operation module 170) through the bus 110, decipher the received instructions, and perform calculation or data processing according to the deciphered instructions.
10

The memory 130 stores instructions or data received from the processor 120 or other
15 elements (e.g., the input/output interface 140, the display 150, the communication interface 160, the application operation module 170, or the like) or generated by the processor 120 or other elements. The memory 130 includes programming modules, such as a kernel 130a, middleware 130b, API (application programming interface) 130c, or an application 130d. Each of the programming modules described above can be formed of software, firmware, and hardware, or a
20 combination thereof.

The kernel 130a controls or manage system resources (for example, the bus 110, the processor 120, the memory 130 or the like) which are used for performing operations or functions implemented by other programming modules, for example, the middleware 130b, the API 130c or the application 130d. Further, the kernel 130a provides an interface through which
25 the middleware 130b, the API 130c, or the application 130d can access and control or manage individual components of the electronic device 100.

The middleware 130b serves as an intermediary that allows the API 130c or the application 130d to communicate with and exchange data with the kernel 130a. Further, in relation to requests for an operation received from the application 130d, the middleware 130b controls (for
30 example, scheduling or load-balancing) the requests for the operation by using, for example, a method of determining sequence for using system resources (for example, the bus 110, the processor 120, the memory 130, or the like) of the electronic device 100 with respect to at least one application among the applications 130d.

- 39 -

The API 130c is an interface by which the application 130d controls functions provided from the kernel 130a or the middleware 130b, and includes, for example, at least one interface or function (for example, instructions) for file control, window control, image processing, or text control.

5 According to various embodiments, the application 130d includes a Short Message Service (SMS)/Multimedia Message Service (MMS) application, an e-mail application, a calendar application, an alarm application, a health care application (for example, an application for measuring the amount of exercise or blood sugar), an environmental information application (for example, an application for providing atmospheric pressure, humidity, or temperature), or the
10 like. Additionally or alternatively, the application 130d can be an application related to information exchange between the electronic device 100 and an external electronic device 104. The application related to the information exchange can include, for example, a notification relay application for transmitting specific information to the external electronic device, or a device management application for managing the external electronic device.

15 For example, the notification relay application can include a function of transferring notification information generated in other applications (for example, the SMS/MMS application, the e-mail application, the health care application, or the environmental information application) of the electronic device 100 to the external electronic device 104. Additionally or alternatively, the notification relay application can receive the notification information from, for example, the
20 external electronic device 104, and can provide the received notification information to a user. The device management application manages (for example, install, delete, or update), for example, at least some functions (for example, turning external electronic device (or some elements) on or off, or adjusting the brightness (or resolution) of a display) of the external electronic device 104 that communicates with the electronic device 100, applications performed
25 in the external electronic device, or services (for example, a phone call service, or a messaging service) provided by the external electronic device.

 According to various embodiments, the application 130d includes applications, which are designated according to the attribute (e.g., device type) of the external electronic device 104. For example, in a case where the external electronic device is an MP3 player, the application 130d
30 includes an application related to the reproduction of music. Similarly, when the external electronic device is a mobile medical device, the application 130d includes an application related to health care. According to an embodiment, the application 130d includes at least one of an

- 40 -

application designated for the electronic device 100 or an application received from a different electronic device (for example, a server 106, or an external electronic device 104).

The input/output interface 140 transmits a command or data input from the user through an input/output device (for example, sensor, keyboard, or touch screen) to the processor 120, the memory 130, the communication interface 160, or the application operation module 170 through, for example, the bus 110. For example, the input/output interface 140 provides, to the processor 120, data for a user's touch which is input through the touch screen. Further, through the input/output device (for example, a speaker or a display), the input/output interface 140 outputs commands or data received from the processor 120, the memory 130, the communication interface 160, or the application operation module 170 through the bus 110. For example, the input/output interface 140 outputs voice data processed by the processor 120 to the user through the speaker.

The display 150 displays various pieces of information (for example, multimedia data or text data) for the user.

The communication interface 160 makes a communication connection between the electronic device 100 and a different electronic device (for example, the external electronic device 104 or the server 106). For example, the communication interface 160 connects to a network 162 through wireless or wired communication to communicate with the external electronic device. The wireless communication includes, for example, at least one of Wi-Fi, Wi-Fi Direct, Bluetooth (BT), Near Field Communication (NFC), a Global Positioning System (GPS), or cellular communication (for example, LTE, LTE-A, CDMA, WCDMA, UMTS, WiMax, GSM, 3G, 4G, 5G, etc.). The wired communication includes at least one of, for example, a Universal Serial Bus (USB, USB 2.0, USB 3.0, USB 3.1, etc.), a High Definition Multimedia Interface (HDMI), Ethernet (802.3, etc.), Recommended Standard 232 (RS-232), and a Plain Old Telephone Service (POTS) port/interface.

According to an embodiment, the network 162 can be a telecommunications network. The communication network can include at least one of a computer network, the Internet, the Internet of things, and a telephone network. According to an embodiment, protocols (for example, a transport layer protocol, a data link layer protocol, or a physical layer protocol) for communication between the electronic device 100 and external electronic devices can be supported by at least one of the application 130d, the API 130c, the middleware 130b, the kernel 130a, and the communication interface 160.

- 41 -

According to an embodiment, the application operation module 170 supports driving of the electronic device 100 by performing at least one of the operations (or functions) implemented by the electronic device 100. For example, the server 106 can include a communication control server module 108 capable of supporting the application operation module 170 implemented in the electronic device 100. For example, the communication control server module 108 can include at least one component of the application operation module 170, and can perform (e.g., perform as a proxy) at least one of the operations performed by the application operation module 170.

The application operation module 170 processes at least some of the information obtained from other components (for example, the processor 120, the memory 130, the input/output interface 140, or the communication interface 160) and utilize the same in various manners. For example, the application operation module 170 controls at least some functions of the electronic device 100 by using the processor 120 or independently thereof so that the electronic device 100 can interwork with a different electronic device (e.g., the external electronic device 104 or the server 106). The connection control module 170 can be integrated into the processor 120. According to an embodiment, at least one component of the application operation module 170 can be included in the server 106 (for example, the communication control server module 108) and can have at least one operation, which is performed by the application operation module 170, supported by the server 106.

Although the present disclosure has been described with an exemplary embodiment, various changes and modifications may be suggested to one skilled in the art. It is intended that the present disclosure encompass such changes and modifications as fall within the scope of the appended claims.

What is claimed is:

REFERENCES

Each reference cited herein (including those aforementioned) is expressly incorporated herein by reference in its entirety.

Aiba, I., Noebels, J.L., 2015. Spreading depolarization in the brainstem mediates sudden cardiorespiratory arrest in mouse SUDEP models. *Sci Transl Med* 7, 282ra246.

Amir, J., Ashkenazi, S., Schonfeld, T., Weitz, R., Nitzan, M., 1983. Laryngospasm as a single manifestation of epilepsy. *Arch Dis Child* 58, 151-153.

Antoniuk, S.A., Oliva, L.V., Bruck, I., Malucelli, M., Yabumoto, S., Castellano, J.L., 2001.

Sudden unexpected, unexplained death in epilepsy autopsied patients. *Arq Neuropsiquiatr* 59, 40-45.

Arito, H., Takahashi, M., Iwasaki, T., Uchiyama, I., 1997. Age-related changes in ventilatory and heart rate responses to acute ozone exposure in the conscious rat. *Ind Health* 35, 78-86.

Bartlett, D., 2011. Upper Airway Motor Systems, *Comprehensive Physiology*. John Wiley & Sons, Inc.

5 Bateman, L.M., Li, C.S., Seyal, M., 2008. Ictal hypoxemia in localization-related epilepsy: analysis of incidence, severity and risk factors. *Brain* 131, 3239-3245.

Bermeo-Ovalle, A.C., Kennedy, J.D., Schuele, S.U., 2015. Cardiac and autonomic mechanisms contributing to SUDEP. *J Clin Neurophysiol* 32, 21-29.

Bernard, C., 2015. Spreading depression: epilepsy's wave of death. *Sci Transl Med* 7, 282fs214. Blitzer, A., Meyer, T., 2006. Neurologic disorders of the larynx, in: Bailey, B.J., Johnson, J.T., Newlands, S.D. (Eds.), *Head & Neck Surgery--otolaryngology* Lippincott Williams & Wilkins, pp. 867-882.

Blum, A.S., 2009. Respiratory physiology of seizures. *J Clin Neurophysiol* 26, 309-315.

15 Brancatisano, A., Dodd, D.S., Engel, L.A., 1991. Posterior cricoarytenoid activity and glottic size during hyperpnea in humans. *J Appl Physiol* (1985) 71, 977-982.

Brostrom, A., Johansson, P., Stromberg, A., Albers, J., Martensson, J., Svanborg, E., 2007. Obstructive sleep apnoea syndrome--patients' perceptions of their sleep and its effects on their life situation. *J Adv Nurs* 57, 318-327.

20 Canteras, N.S., Swanson, L.W., 1992. Projections of the ventral subiculum to the amygdala, septum, and hypothalamus: a PHAL anterograde tract-tracing study in the rat. *J Comp Neurol* 324, 180-194.

Devinsky, O., 2011. Sudden, unexpected death in epilepsy. *N Engl J Med* 365, 1801-1811.

Donzelli, J., Brady, S., 2004. The effects of breath-holding on vocal fold adduction: implications for safe swallowing. *Arch Otolaryngol Head Neck Surg* 130, 208-210.

Ead, H., 2003. Review of laryngospasm and noncardiogenic pulmonary edema. *Dynamics* 14, 9-12.

25 Faingold, C.L., Randall, M., Tupal, S., 2010. DBA/1 mice exhibit chronic susceptibility to audiogenic seizures followed by sudden death associated with respiratory arrest. *Epilepsy Behav* 17, 436-440.

Geerling, J.C., Shin, J.W., Chimenti, P.C., Loewy, A.D., 2010. Paraventricular hypothalamic nucleus: axonal projections to the brainstem. *J Comp Neurol* 518, 1460-1499.

Greene, E.C., 1968. *Anatomy of the rat*. Hafner Pub. Co., New York,.

30 Herreras, O., Largo, C., Ibarz, J.M., Somjen, G.G., Martin del Rio, R., 1994. Role of neuronal synchronizing mechanisms in the propagation of spreading depression in the in vivo hippocampus. *J Neurosci* 14, 7087-7098.

Hotta, H., Koizumi, K., Stewart, M., 2009. Cardiac sympathetic nerve activity during kainic acid-induced limbic cortical seizures in rats. *Epilepsia* 50, 923-927.

Johnston, S.C., Horn, J.K., Valente, J., Simon, R.P., 1995. The role of hypoventilation in a sheep model of epileptic sudden death. *Ann Neurol* 37, 531-537.

- 5 Johnston, S.C., Siedenberg, R., Min, J.K., Jerome, E.H., Laxer, K.D., 1997. Central apnea and acute cardiac ischemia in a sheep model of epileptic sudden death. *Ann Neurol* 42, 588- 594.

Kuna, S.T., Day, R.A., Insalaco, G., Villeponteaux, R.D., 1991. Posterior cricoarytenoid activity in normal adults during involuntary and voluntary hyperventilation. *J Appl Physiol* (1985) 70, 1377-1385.

- 10 Kuna, S.T., Insalaco, G., Woodson, G.E., 1988. Thyroarytenoid muscle activity during wakefulness and sleep in normal adults. *J Appl Physiol* (1985) 65, 1332-1339.

Kuna, S.T., Smickley, J.S., Insalaco, G., 1990. Posterior cricoarytenoid muscle activity during wakefulness and sleep in normal adults. *J Appl Physiol* (1985) 68, 1746-1754.

Langan, Y., 2000. Sudden unexpected death in epilepsy (SUDEP): risk factors and case control studies. *Seizure* 9, 179-183.

- 15 Lathers, C.M., Schraeder, P.L., Boggs, J.G., 1998. Sudden unexplained death and autonomic dysfunction., in: Engel, J., Pedley, T.A. (Eds.), *Epilepsy : a comprehensive textbook*. Lippincott-Raven, Philadelphia, pp. 1943-1955, chapter 1183.

Lathers, C.M., Schraeder, P.L., Bungo, M.W., 2008. The mystery of sudden death: mechanisms for risks. *Epilepsy Behav* 12, 3-24.

- 20 Lauritzen, M., Dreier, J.P., Fabricius, M., Hartings, J.A., Graf, R., Strong, A.J., 2011. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. *J Cereb Blood Flow Metab* 31, 17-35.

Leaming, J.M., Temdrup, T.E., Ognibene, S., 1999. Glottal patency during experimental cortical seizures in piglets. *Acad Emerg Med* 6, 682-687.

- 25 Leao, A.A., 1986. Spreading depression. *Funct Neurol* 1, 363-366.

Mascareno, E., Galatioto, J., Rozenberg, I., Saliccioli, L., Kamran, H., Lazar, J.M., Liu, F., Pedrazzini, T., Siddiqui, M.A., 2012. Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor beta (TGF-beta1) signaling axis. *J Biol Chem* 287, 13084-13093.

- 30 Massey, C.A., Sowers, L.P., Dlouhy, B.J., Richerson, G.B., 2014. Mechanisms of sudden unexpected death in epilepsy: the pathway to prevention. *Nat Rev Neurol* 10, 271-282.

Mendelsohn, M.S., Martin, R.E., 1993. Airway protection during breath-holding. *The Annals of otology, rhinology, and laryngology* 102, 941-944.

Miller, W.F., Scacci, R., Gast, L.R., 1987. Laboratory evaluation of pulmonary function. Lippincott, Philadelphia.

Mor, N., Naggar, I., Das, O., Nakase, K., Silverman, J.B., Sundaram, K., Stewart, M., Kollmar, R., 2014. Quantitative video laryngoscopy to monitor recovery from recurrent laryngeal nerve injury in the rat. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery* 150, 824-826.

Morentin, B., Alcaraz, R., 2002. [Sudden unexpected death in epilepsy in children and adolescents]. *Rev Neurol* 34, 462-465.

Murray-Calderon, P., Connolly, M.A., 1997. Laryngospasm and noncardiogenic pulmonary edema. *Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses / American Society of PeriAnesthesia Nurses* 12, 89-94.

Naggar, I., Stewart, M., 2015. A rat model for exploring the contributions of ventricular arrhythmias to sudden death in epilepsy, in: Lathers, C.M., Schraeder, P.L., Leestma, J.E., Wannamaker, B.B., Richard L. Verrier, F.A.C.C., Schachter, S.C. (Eds.), *Sudden Unexpected Death in Epilepsy: Mechanisms and New Methods for Analyzing Risks*. Taylor & Francis, pp. 241-250.

Naggar, I., Uchida, S., Kamran, H., Lazar, J., Stewart, M., 2012. Autonomic boundary conditions for ventricular fibrillation and their implications for a novel defibrillation technique. *J Physiol Sci* 62, 479-492.

Nei, M., Hays, R., 2010. Sudden unexpected death in epilepsy. *Curr Neurol Neurosci Rep* 10, 319-326.

Paxinos, G., Watson, C., 1998. *The rat brain in stereotaxic coordinates*, 4th ed. Academic Press, San Diego.

Renninger, J.P., 2006. Head-out plethysmography in safety pharmacology assessment. *Curr Protoc Pharmacol* Chapter 10, Unit10 11.

Ryvlin, P., Nashef, L., Lhatoo, S.D., Bateman, L.M., Bird, J., Bleasel, A., Boon, P., Crespel, A., Dworetzky, B.A., Hogenhaven, H., Lerche, H., Maillard, L., Malter, M.P., Marchal, C., Murthy, J.M., Nitsche, M., Patariaia, E., Rabben, T., Rheims, S., Sadzot, B., Schulze- Bonhage, A., Seyal, M., So, E.L., Spitz, M., Szucs, A., Tan, M., Tao, J.X., Tomson, T., 2013. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. *Lancet Neurol* 12, 966-977.

Saito, T., Sakamoto, K., Koizumi, K., Stewart, M., 2006. Repeatable focal seizure suppression: a rat preparation to study consequences of seizure activity based on urethane anesthesia and reversible carotid artery occlusion. *J Neurosci Methods* 155, 241-250.

Sakamoto, K., Saito, T., Orman, R., Koizumi, K., Lazar, J., Saliccioli, L., Stewart, M., 2008.

Autonomic consequences of kainic acid-induced limbic cortical seizures in rats: peripheral autonomic nerve activity, acute cardiovascular changes, and death. *Epilepsia* 49, 982-996.

Salmo, E.N., Connolly, C.E., 2002. Mortality in epilepsy in the west of Ireland: a 10-year review. *Ir J Med Sci* 171, 199-201.

Schraeder, P.L., Lathers, C.M., 1983. Cardiac neural discharge and epileptogenic activity in the cat: an animal model for unexplained death. *Life Sci* 32, 1371-1382.

- 5 Seyal, M., Bateman, L.M., Albertson, T.E., Lin, T.C., Li, C.S., 2010. Respiratory changes with seizures in localization-related epilepsy: Analysis of periictal hypercapnia and airflow patterns. *Epilepsia*.

Shorvon, S., Tomson, T., 2011. Sudden unexpected death in epilepsy. *Lancet* 378, 2028-2038. Somjen, G.G., Aitken, P.G., Czeh, G.L., Herreras, O., Jing, J., Young, J.N., 1992. Mechanism of spreading depression: a review of recent findings and a hypothesis. *Can J Physiol Pharmacol* 70 Suppl, S248-254.

- 10 Sowers, L.P., Massey, C.A., Gehlbach, B.K., Granner, M.A., Richerson, G.B., 2013. Sudden unexpected death in epilepsy: fatal post-ictal respiratory and arousal mechanisms. *Respiratory physiology & neurobiology* 189, 315-323.

Stewart, M., 2008. Is an abrupt "cerebral electrical shutdown" during a seizure the mechanism of SUDEP?, *J Neurol Neurosurg Psychiatry*, eLetter: jnnp.bmj.com/cgi/eletters/78/12/1395#3299, 1312 Feb 2008.

- 15 Stewart, M., 2011. The urethane/kainate seizure model as a tool to explore physiology and death associated with seizures, in: Lathers, C.M., Schraeder, P.L., Bungo, M.W., Leetsma, J.E. (Eds.), *Sudden Death in Epilepsy: Forensic and Clinical Issues*. Taylor & Francis Group, Boca Raton, FL, pp. 627-644.

Surges, R., Sander, J.W., 2012. Sudden unexpected death in epilepsy: mechanisms, prevalence, and prevention. *Curr Opin Neurol* 25, 201-207.

- 20 Tavee, J., Morris, H., 3rd, 2008. Severe postictal laryngospasm as a potential mechanism for sudden unexpected death in epilepsy: a near-miss in an EMU. *Epilepsia* 49, 2113-2117.

Terndrup, T.E., Gregory, M.E., Fordyce, W.E., 1995a. The role of the upper airway in contributing to respiratory responses during experimental seizures in piglets. *Pediatr Res* 38, 61-66.

- 25 Terndrup, T.E., Kadison, A., Woo, P., 1995b. Glottal patency during experimental seizures in piglets. *Pediatr Res* 38, 932-937.

Thurman, D.J., Hesdorffer, D.C., French, J.A., 2014. Sudden unexpected death in epilepsy: assessing the public health burden. *Epilepsia* 55, 1479-1485.

Tolstykh, G.P., Cavazos, J.E., 2013. Potential mechanisms of sudden unexpected death in epilepsy. *Epilepsy Behav* 26, 410-414.

- 30 Umbrain, V., Camu, F., 1993. Acute pulmonary edema after laryngospasm. *Acta anaesthesiologica Belgica* 44, 149-153.

Uteshev, V.V., Tupal, S., Mhaskar, Y., Faingold, C.L., 2010. Abnormal serotonin receptor expression in DBA/2 mice associated with susceptibility to sudden death due to respiratory arrest. *Epilepsy Res* 88, 183-188.

- 46 -

Venit, E.L., Shepard, B.D., Seyfried, T.N., 2004. Oxygenation Prevents Sudden Death in Seizure-prone Mice. *Epilepsia* 45, 993-996.

Wannamaker, B.B., 1985. Autonomic nervous system and epilepsy. *Epilepsia* 26 Suppl 1, S31- 39.

Weiss, J.W., Tamisier, R., Liu, Y., 2015. Sympathoexcitation and Arterial Hypertension Associated
5 with Obstructive Sleep Apnea and Cyclic Intermittent Hypoxia. *J Appl Physiol* (1985), jap 00315 02015.

- 47 -

CLAIMS

1. A method for detecting obstructive apnea, comprising:

receiving a bioelectric signal from a mammal comprising electromyographic activity of muscles of respiration;

5 processing the bioelectric signal to isolate electromyographic activity;

determining a timing and amplitude of inspiratory efforts based on the isolated electromyographic activity;

determining a baseline amplitude of inspiratory efforts;

10 comparing an amplitude of inspiratory efforts with the determined baseline amplitude of inspiratory efforts; and

determining occurrence of obstructive apnea if a series of inspiratory efforts have increasing amplitude over time, above the baseline amplitude.

2. The method according to claim 1, further comprising determining a baseline timing range of inspiratory efforts, and comparing the timing of inspiratory efforts with the determined
15 baseline timing of inspiratory efforts, wherein the occurrence of obstructive apnea is determined if a series of inspiratory efforts have increasing amplitude above the baseline amplitude over time, and a timing within the baseline timing range.

3. The method according to claim 1, wherein the bioelectric signal is an electrocardiographic signal.

20 4. The method according to claim 3, wherein the timing and amplitude of inspiratory efforts are determined over a series of at least three inspiratory efforts before the occurrence of obstructive apnea is determined.

5. The method according to claim 1, wherein the bioelectric signal is an electroencephalographic signal.

25 6. The method according to claim 1, wherein the bioelectric signal is acquired from a single extremity.

7. The method according to claim 1, further comprising generating an audible alarm in response to determining the occurrence of obstructive apnea.

30 8. The method according to claim 1, further comprising selectively wirelessly communicating a signal in response to determining the occurrence of obstructive apnea.

9. The method according to claim 1, wherein:

- 48 -

said receiving a bioelectric signal from a mammal comprising electromyographic activity comprises receiving at least one of an electrocardiographic signal, an electroencephalographic signal, and an electromyographic signal; and

5 said processing the bioelectric signal to isolate electromyographic activity comprises at least
subjecting the bioelectric signal to a bandpass filter having a passband between about 300 Hz
and 1 kHz.

10. The method according to claim 1, wherein said processing the bioelectric signal to isolate electromyographic activity comprises determining a signal power within a passband over time.

10 11. The method according to claim 1, wherein said comparing an amplitude of inspiratory
efforts with the determined baseline amplitude of inspiratory efforts comprises comparing a
series of amplitudes and timings of inspiratory efforts with a baseline window representing a
normal range of amplitudes and timings of inspiratory efforts.

15 11. The method according to claim 1, wherein said determining occurrence of obstructive
apnea if a series of inspiratory efforts have increasing amplitude over time, above the baseline
amplitude, comprises determining if three successive inspiratory efforts have an amplitude above
a threshold with at least one of a steady amplitude and an increasing amplitude, while an interval
between inspiratory efforts is within a normal range.

12. A method of determining obstructive apnea, comprising:

20 determining a baseline inter-heartbeat interval and a normal range of variation for a
respective respiratory rate within a respiratory interval;

 determining an inter-heartbeat interval and a respiratory rate of a patient;

 determining a commencement of a series of at least one inter-heartbeat interval which is
outside the normal range of variation, below the baseline inter-heartbeat interval, for the
respective respiratory rate; and

25 determining commencement of obstructive apnea if within the respiratory interval, a number
of commencements of the series of the at least one inter-heartbeat interval which is outside the
normal range of variation, below the baseline inter-heartbeat interval for the respective
respiratory rate, is above a threshold.

13. The method according to claim 12, wherein the threshold is three.

30 14. The method according to claim 12, wherein the inter-heartbeat interval and the
respiratory rate are determined based on a bioelectric signal.

15. The method according to claim 14, wherein the bioelectric signal is at least one of an
electrocardiographic signal, an electroencephalographic signal, and an electromyographic signal.

- 49 -

16. The method according to claim 14 wherein the bioelectric signal is acquired from a single extremity.

17. The method according to claim 12, further comprising selectively generating at least one of an audible alarm and a wireless communication, in response to determining the
5 commencement of obstructive apnea.

18. The method according to claim 12, further comprising automatically generating an e911 (enhanced 911) call through a telephone network in response to determining the commencement of obstructive apnea.

19. The method according to claim 12, wherein the inter-heartbeat interval is determined by
10 determining an R-R interval of an electrocardiogram, further comprising:

establishing a window distinguishing a normal inter-heartbeat interval from a short inter-heartbeat interval for the respective respiratory rate; and

recording a time of inter-heartbeat intervals which is outside the window for the respective respiratory rate.

15 20. A system for detecting obstructive apnea, comprising an input configured to receive a bioelectric signal from a mammal comprising at least one of electromyographic activity of muscles of respiration, and information defining an inter-heartbeat interval; an output for communicating a signal dependent on a determined occurrence of obstructive apnea; and at least one processor configured to at least one of: (a)(1) process the bioelectric signal to isolate electromyographic
20 activity; (2) determine a baseline amplitude of inspiratory efforts based on the isolated electromyographic activity; and (3) determine occurrence of obstructive apnea if a series of inspiratory efforts over time have increasing amplitude, above the baseline amplitude of inspiratory efforts determined dependent on the isolated electromyographic activity; and (b) (1) determine a baseline inter-heartbeat interval and a normal range of variation for a respective respiratory rate
25 within a respiratory interval; (2) determine an inter-heartbeat interval and a respiratory rate of a patient; (3) determine a commencement of a series of inter-heartbeat intervals which is outside the normal range of variation below the baseline inter-heartbeat interval for the respective respiratory rate; and (4) determine commencement of obstructive apnea if a number of commencements of the series of at least one inter-heartbeat interval which is below the baseline inter-heartbeat interval for
30 the respective respiratory rate within the respiratory interval is above a threshold.




Fig. 1A

Changes in RR interval during occlusion




Fig. 1B

Correlation of PIP with artifact size




Fig. 1C

Fig. 1D




Fig. 1E






Fig. 2



Plethysmograph volume vs. Time (min)

A1. Non-intubated Baseline



Plethysmograph volume vs. Time (min)

B1. Intubated Baseline

Fig. 3-1





Fig. 3-2





Fig. 3-3







Fig. 3-4








Fig. 5




Obstructive



Central

Obstructive Apnea



Central Apnea





Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 11




Fig. 12 Prior Art




Fig. 13 Prior Art




Fig. 14 Prior Art




Fig. 15 Prior Art




Fig. 16 Prior Art




Fig. 17 Prior Art




Fig. 18 Prior Art

Table 1
Upper-Airway Obstruction During Seizures

Respiratory Parameter	Difference Score (Seizure Minus Pre-Seizure)		
	Non-Intubated (N = 11)	Intubated (N = 5)	p-Value
Respiratory Rate (min ⁻¹)	286 ± 56	196 ± 37	0.017
Tidal Volume (ml)	-1.05 ± 0.37	-0.51 ± 0.50	0.12
Minute Ventilation (ml·min ⁻¹)	-24 ± 40	-2 ± 40	0.65
Peak-Inspiratory-Flow to Peak-Expiratory-Flow Ratio	-0.51 ± 0.31	0.54 ± 0.41	0.002

Table 2						
COMPARISON OF CONSEQUENCES OF OBSTRUCTIVE AND CENTRAL APNEA						
	obstructive apnea		p	central apnea		p (df, t)
	non-intubated	intubated		non-intubated	intubated	
rats with apneic periods ≥ 1 s (total N)	7 (11)	0 (5)	0.034	6 (11)	5 (5)	NS
number of apneic periods	7			31	18	
duration	103.3 ± 42.2			7.3 ± 5.7	7.4 ± 10.6	NS
rats with apneic periods > 5 s	7	0		5	1	NS
number of apneic periods	7			15	5	
duration	103.3 ± 42.2			12.1 ± 4.4	21.0 ± 12.5	NS
maximum duration	162			23	33	
mean HR (pre-apnea) bps	3.8 ± 0.4			4.1 ± 0.5 (pooled)		NS
mean HR (apnea @ 5-15 s) bps	3.1 ± 0.6 (p=0.036; df=6; t=2.7)			3.8 ± 0.7 (NS)		0.025 (14, 2.5)
minimum HR (apnea @ 5-15 s) bps	2.6 ± 0.5 (p=0.005; df=6; t=4.4)			3.6 ± 0.7 (p=0.023; df=8; t=2.8)		0.002 (14, 3.9)
ST changes within 15 s?	yes			no		
max % change (mean +/- SEM)	-31.4 ± 17.3, n=7			-13.9 ± 9.7, n=9		0.019 (14, 2.6)

Table 3

	kainic acid only lesion, then kainic acid								bilateral SLN				intubated, then kainic acid				group by group seizure		
	baseline	seizure	b:s	baseline	seizure	b:l	SLN	baseline	intubated	seizure	b:l	is	baseline	intubated	seizure	b:l			
number of animals in the group	5			6					5								IntSLN	IntKA	KA:SLN
average number respiratory cycles per rat per group	439.8	1244.8		402.0	402.0	1418.6			426.4	452.0	1100.6								
respiratory rate (breaths/min)	89.0	370.9	0*	81.8	80.8	370.7	NS	0	100.2	98.3	294.8	NS	0	NS	NS	NS	NS	NS	NS
average tidal volume (ml)	1.24	0.46	0.008	1.77	1.72	0.46	NS	0	1.25	1.04	0.53	NS	NS	NS	NS	NS	NS	NS	NS
minute ventilation (ml/min)	108.0	94.4	NS	144.6	138.8	106.1	NS	0	124.2	95.3	93.3	NS	NS	NS	NS	NS	NS	NS	NS
peak inspiratory flow / peak expiratory flow	0.95	0.60	NS	1.18	1.11	0.46	NS	0.001	1.13	1.02	1.56	NS	0.011	0	0	NS	NS	NS	NS
peak inspiratory flow (ml/s)	-6.82	-5.34	NS	-8.62	-8.64	-6.02	NS	0.002	-6.83	-5.79	-5.43	NS	NS	NS	NS	NS	NS	NS	NS
peak expiratory flow (ml/s)	7.56	5.24	NS	7.75	8.12	5.65	NS	NS	6.03	6.00	4.81	NS	NS	NS	NS	NS	NS	NS	NS
duration of inspiration (s)	0.36	0.11	0.001	0.35	0.37	0.10	NS	0	0.27	0.32	0.12	NS	0.003	NS	NS	NS	NS	NS	NS
duration of expiration (s)	0.33	0.13	0	0.39	0.38	0.12	NS	0	0.34	0.31	0.16	NS	0	0.046	NS	NS	NS	NS	NS
inspiratory tidal volume (ml)	-1.24	-0.46	0.008	-1.77	-1.72	-0.46	NS	0	-1.26	-1.04	-0.53	NS	NS	NS	NS	NS	NS	NS	NS
expiratory tidal volume (ml)	1.24	0.46	0.008	1.77	1.72	0.46	NS	0	1.25	1.04	0.53	NS	NS	NS	NS	NS	NS	NS	NS
time when 25% of tidal volume has been inspired (s)	0.17	0.04	0.035	0.13	0.15	0.03	NS	0.004	0.09	0.15	0.04	NS	0.041	NS	NS	NS	NS	NS	NS
time when 50% of tidal volume has been inspired (s)	0.22	0.06	0.011	0.19	0.21	0.05	NS	0.001	0.14	0.20	0.07	NS	0.016	NS	NS	NS	NS	NS	NS
time when 75% of tidal volume has been inspired (s)	0.27	0.08	0.003	0.25	0.27	0.07	NS	0	0.19	0.24	0.09	NS	0.007	NS	NS	NS	NS	NS	NS
time when 25% of tidal volume has been expired (s)	0.07	0.03	0.012	0.09	0.09	0.03	NS	0	0.07	0.07	0.04	NS	0	NS	NS	NS	NS	NS	NS

time when 50% of tidal volume has been expired (s)	0.12	0.05	0.014	0.16	0.16	0.05	NS	0	0.13	0.11	0.06	NS	0	0.046	NS	NS
time when 75% of tidal volume has been expired (s)	0.18	0.07	0.016	0.25	0.24	0.07	NS	0	0.20	0.17	0.09	NS	0	0.041	NS	NS
flow when 25% of tidal volume has been inspired (ml/s)	-6.04	-4.46	NS	-6.93	-6.74	-5.02	NS	NS	-6.09	-4.68	-4.48	NS	NS	NS	NS	NS
flow when 50% of tidal volume has been inspired (ml/s)	-6.09	-5.12	NS	-7.90	-7.99	-5.77	NS	0.009	-6.40	-5.43	-5.22	NS	NS	NS	NS	NS
flow when 75% of tidal volume has been inspired (ml/s)	-5.31	-4.76	NS	-7.03	-6.88	-5.21	NS	0.007	-5.69	-4.94	-4.91	NS	NS	NS	NS	NS
flow when 25% of tidal volume has been expired (ml/s)	7.38	4.95	NS	6.70	6.60	5.21	NS	NS	5.84	5.77	4.58	NS	NS	NS	NS	NS
flow when 50% of tidal volume has been expired (ml/s)	6.47	4.92	NS	6.61	6.30	5.36	NS	NS	5.11	5.27	4.43	NS	NS	NS	NS	NS
flow when 75% of tidal volume has been expired (ml/s)	4.65	3.65	NS	4.91	4.94	4.15	NS	NS	3.90	3.67	3.32	NS	NS	NS	NS	NS
* a "0" indicates p<0.0001																

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/061099

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61B5/024 A61B5/0456 A61B5/0488 A61B5/08 A61B5/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/018737 A1 (CARDIAC PACEMAKERS INC [US]) 3 March 2005 (2005-03-03) abstract page 43, line 4 - page 48, line 19 figures 16A-16F	20
X	US 2010/217133 A1 (NILSEN KRIS [AU] ET AL) 26 August 2010 (2010-08-26) the whole document	20



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

26 January 2018

Date of mailing of the international search report

02/02/2018

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Marteau, Frédéric

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2017/061099

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **1-19**
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Claims Nos.: 1-19

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Claims 1-11 relate to a method of diagnostic on human or animal body, because they comprise the four steps acknowledged to form a diagnostic method practised on the human or animal body. In claim 1, the step of 'receiving a bioelectric signal...' constitutes the examination phase, whereas the 'comparing an amplitude...' comprises both the comparison and finding of any significant deviation with standard value ('baseline amplitude'). Finally, the step of 'determining the occurrence of obstructive apnea' is considered to constitute the decision phase. Concerning the examination phase, receiving a bioelectrical signal requires the presence of the body as from the description such method is intended for online monitoring an individual (see page 14 lines 20-21 and page 11 lines 17-21). This Authority is not required to search the present application with respect to the aforementioned claims (Article 17(2)(b) PCT and Rule 39.1(iv) PCT). Consequently, no International Search Report and no Written Opinion (Rule 67.1 PCT in combination with Rule 43bis.1(b) PCT) have been established with respect to them. Claims 12-19 relate to a method of diagnostic on human or animal body, because they comprise the four steps acknowledged to form a diagnostic method practised on the human or animal body. In claim 12, the step of acquiring a bioelectric signal (essential feature missing) constitutes the examination phase, whereas the 'determining a commencement of a series...' comprises both the comparison and finding of any significant deviation with standard value ('normal range of variation'). Finally, the step of 'determining commencement of obstructive apnea...' is considered to constitute the decision phase. Concerning the examination phase, receiving a bioelectrical signal requires the presence of the body as from the description such method is intended for online monitoring an individual (see page 14 lines 20-21 and page 11 lines 17-21). This Authority is not required to search the present application with respect to the aforementioned claims (Article 17(2)(b) PCT and Rule 39.1(iv) PCT). Consequently, no International Search Report and no Written Opinion (Rule 67.1 PCT in combination with Rule 43bis.1(b) PCT) have been established with respect to them. The subject-matter of claims 1-11 and 12-19 is considered to be a pure mental act. In particular, the method of claims 1-11 and 12-19 has no technical features that prevents a person from carrying out the method purely in his or her mind. This Authority is not required to search the present application with respect to the aforementioned claims (Article 17(2)(b) PCT and Rule 39.1(iii) PCT). Consequently, no International Search Report and no Written Opinion (Rule 67.1 PCT in combination with Rule 43bis.1(b) PCT) have been established with respect to them.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/061099

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005018737 A1	03-03-2005	AT 397475 T EP 1656181 A1 EP 1938862 A2 WO 2005018737 A1	15-06-2008 17-05-2006 02-07-2008 03-03-2005
US 2010217133 A1	26-08-2010	AU 2008307127 A1 CA 2697631 A1 CN 101815465 A EP 2203115 A1 JP 5303802 B2 JP 2010540124 A KR 20100045521 A US 2010217133 A1 WO 2009043087 A1	09-04-2009 09-04-2009 25-08-2010 07-07-2010 02-10-2013 24-12-2010 03-05-2010 26-08-2010 09-04-2009

专利名称(译)	气道阻塞的系统，方法和生物标志物		
公开(公告)号	EP3537961A1	公开(公告)日	2019-09-18
申请号	EP2017808261	申请日	2017-11-10
[标]申请(专利权)人(译)	找到了状态UNIVERSIRTY纽约RES		
申请(专利权)人(译)	研究基金会纽约州立大学		
当前申请(专利权)人(译)	研究基金会纽约州立大学		
[标]发明人	STEWART MARK KOLLMAR RICHARD LAZAR JASON		
发明人	STEWART, MARK KOLLMAR, RICHARD LAZAR, JASON		
IPC分类号	A61B5/024 A61B5/0456 A61B5/0488 A61B5/08 A61B5/00		
CPC分类号	A61B5/024 A61B5/0456 A61B5/0488 A61B5/0826 A61B5/4818 A61B5/746		
优先权	62/420308 2016-11-10 US		
外部链接	Espacenet		

摘要(译)

为阻塞性呼吸暂停提供了两种生物标志物。第一生物标志物确定来自生物电信号的吸气努力的幅度和时间。将呼吸率与正常的预检率进行比较，并将努力的幅度与正常幅度进行比较。如果一系列吸气努力超过正常幅度并且幅度增加，但是以正常速率，则阻塞性呼吸暂停可能存在。第二种生物标志物决定心率和呼吸频率。建立心跳间隔的正常下阈值，并且如果发生亚阈值事件（短RR间隔），则针对呼吸率正常化窗口比较每个亚阈值事件序列的开始时间。如果亚阈值事件的数量超过窗口的最小值，则可能存在阻塞性呼吸暂停。